US20230355758A1 - Pharmaceutical Formulations - Google Patents
Pharmaceutical Formulations Download PDFInfo
- Publication number
- US20230355758A1 US20230355758A1 US18/152,872 US202318152872A US2023355758A1 US 20230355758 A1 US20230355758 A1 US 20230355758A1 US 202318152872 A US202318152872 A US 202318152872A US 2023355758 A1 US2023355758 A1 US 2023355758A1
- Authority
- US
- United States
- Prior art keywords
- cyclodextrin
- antibody
- beta
- low bone
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 75
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 106
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims abstract description 104
- 239000007788 liquid Substances 0.000 claims abstract description 73
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 60
- 229930182817 methionine Natural products 0.000 claims abstract description 60
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 52
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 239000012634 fragment Substances 0.000 claims abstract description 44
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 27
- 208000020084 Bone disease Diseases 0.000 claims abstract description 22
- 238000001556 precipitation Methods 0.000 claims abstract description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 16
- 239000011707 mineral Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 14
- 230000011164 ossification Effects 0.000 claims abstract description 12
- 230000037118 bone strength Effects 0.000 claims abstract description 11
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 58
- 239000012669 liquid formulation Substances 0.000 claims description 43
- 239000001116 FEMA 4028 Substances 0.000 claims description 41
- 229960004853 betadex Drugs 0.000 claims description 41
- 229950010968 romosozumab Drugs 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 28
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 24
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 24
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 24
- 229940068977 polysorbate 20 Drugs 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 20
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 19
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 18
- 239000001639 calcium acetate Substances 0.000 claims description 18
- 229960005147 calcium acetate Drugs 0.000 claims description 18
- 235000011092 calcium acetate Nutrition 0.000 claims description 18
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims description 17
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 17
- 102000058171 human SOST Human genes 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 13
- 239000001632 sodium acetate Substances 0.000 claims description 13
- 235000017281 sodium acetate Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- PCWPQSDFNIFUPO-VDQKLNDWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-37,39,41,43,45,47,49-heptakis(2-hydroxyethoxy)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38,40,42,44,46,48-heptol Chemical compound OCCO[C@H]1[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]1O[C@@H]2CO)[C@@H](O)[C@@H]8OCCO)[C@@H](O)[C@@H]7OCCO)[C@@H](O)[C@@H]6OCCO)[C@@H](O)[C@@H]5OCCO)[C@@H](O)[C@@H]4OCCO)[C@@H](O)[C@@H]3OCCO PCWPQSDFNIFUPO-VDQKLNDWSA-N 0.000 claims description 9
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 9
- DSDAICPXUXPBCC-MWDJDSKUSA-N trimethyl-β-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)OC)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)OC)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)OC)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)OC)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)OC)O3)[C@H](OC)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@@H]3O[C@@H]1COC DSDAICPXUXPBCC-MWDJDSKUSA-N 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 7
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 7
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 6
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 37
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 206010065687 Bone loss Diseases 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 20
- 238000000502 dialysis Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 235000010755 mineral Nutrition 0.000 description 12
- -1 cyclic oligosaccharides Chemical class 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 229940097362 cyclodextrins Drugs 0.000 description 10
- 229940122361 Bisphosphonate Drugs 0.000 description 9
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 150000004663 bisphosphonates Chemical group 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000010392 Bone Fractures Diseases 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000019307 Sclerostin Human genes 0.000 description 7
- 108050006698 Sclerostin Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- PLHMLIDUVYHXHF-ZQSHRCRISA-N 2,6-di-o-ethyl-β-cyclodextrin Chemical compound CCOC[C@H]([C@H]([C@@H]([C@H]1OCC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC)[C@H]([C@@H]([C@H]3OCC)O)O[C@H]3O[C@H](COCC)[C@H]([C@@H]([C@H]3OCC)O)O[C@H]3O[C@H](COCC)[C@H]([C@@H]([C@H]3OCC)O)O[C@H]3O[C@H](COCC)[C@H]([C@@H]([C@H]3OCC)O)O3)[C@H](O)[C@H]2OCC)COCC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OCC)[C@@H]3O[C@@H]1COCC PLHMLIDUVYHXHF-ZQSHRCRISA-N 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000123 anti-resoprtive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009295 crossflow filtration Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 150000001945 cysteines Chemical class 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000001322 periplasm Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 101000578492 Escherichia coli Lysis protein Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 241000577979 Peromyscus spicilegus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101150098533 SOST gene Proteins 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940062527 alendronate Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000011021 bench scale process Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003054 facial bone Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- FWIVDMJALNEADT-SFTDATJTSA-N (2s)-n-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1s)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide Chemical compound C1=CC([C@H](N[C@@H](CC(C)(F)C)C(=O)NC2(CC2)C#N)C(F)(F)F)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 FWIVDMJALNEADT-SFTDATJTSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LMVGXBRDRZOPHA-UHFFFAOYSA-N 2-[dimethyl-[3-(16-methylheptadecanoylamino)propyl]azaniumyl]acetate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O LMVGXBRDRZOPHA-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
- DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000003274 CINCA syndrome Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000000088 Enchondromatosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000017670 Juvenile Paget disease Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- PTVXQARCLQPGIR-DHVFOXMCSA-N L-fucopyranose 1-phosphate Chemical compound C[C@@H]1OC(OP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O PTVXQARCLQPGIR-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000003263 MASS syndrome Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000702766 Mus musculus Sclerostin Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 108700006385 OmpF Proteins 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000013612 Parathyroid disease Diseases 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000002607 Pseudarthrosis Diseases 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 201000010096 SOST-related sclerosing bone dysplasia Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000008321 Winchester syndrome Diseases 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940090568 combinations of vitamin Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000024884 ischemic bone disease Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150036274 kil gene Proteins 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 201000000022 melorheostosis Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- NZXVYLJKFYSEPO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229950009755 odanacatib Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 208000029985 osteonecrosis of the jaw Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 206010031281 osteopoikilosis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000009912 sclerosteosis Diseases 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229940112726 skelid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003438 strontium compounds Chemical class 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
- 229960001023 tibolone Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 150000008501 α-D-glucopyranosides Chemical group 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Definitions
- the present invention belongs to the field of pharmaceutical formulations. More specifically, it relates to a pharmaceutical formulation comprising an antibody, cyclodextrin and methionine.
- Antibodies are large and complex molecules and are inherently chemically and physically instable when stored over a period of time at high concentration. Typical chemical instability may result in deamidation, hydrolysis, oxidation, beta-elimination or disulfide exchanges. Physical instability can result in denaturation, aggregation or precipitation.
- Antibodies can be formulated in freeze-dried, i.e. lyophilized form for reconstitution in a solvent shortly before administration. Freeze-dried formulations of antibodies tend to be more stable than liquid water-based formulation as water is either a reactant or facilitates the transfer of reactants and is thus critical to chemical degradation and protein instability. Despite being less stable, interest has recently focused on liquid formulations of antibodies. These formulations are easier and more convenient for the patient and the healthcare professional to handle and administer in comparison to freeze-dried formulations. Liquid formulations do not need to be reconstituted and can be administered with minimal preparation. However, the stabilization of proteins in liquid formulations to avoid or minimize aggregation, precipitation or degradation remains a particular challenge.
- Aggregation with the formation of insoluble matter or precipitate, is a particular problem. This may cause various problems. Firstly aggregate formation may result in the antibody being less or no longer active; aggregate may provoke undesired and unexpected immunological reactions upon administration and finally aggregates may prevent proper administration of the pharmaceutical formulation e.g. by blocking syringes or pumps. These problems are even more evident in liquid formulations for subcutaneous administration where antibodies are present at high concentrations in much smaller volumes than intravenous infusions.
- a typical strategy for preventing aggregation is to add stabilizers to the antibody formulation.
- stabilizers include sugars, salts, free amino acids, polyols, polyethylene glycols (PEGs), and other polymers, such as polysorbates or poloxamers that may reduce protein-protein interactions.
- Cyclodextrins (sometimes called cycloamyloses) are a family of compounds made up of sugar molecules bound together in a ring (cyclic oligosaccharides). Cyclodextrins are produced from starch by means of enzymatic conversion. They are considered safe and are widely used in food, pharmaceutical drug delivery, and chemical industries, as well as agriculture and environmental engineering. Cyclodextrins are composed of 5 or more ⁇ -D-glucopyranoside units linked 1->4, as in amylose.
- Typical cyclodextrins contain 6 (alpha-cyclodextrin), 7 (beta-cyclodextrin) or 8 (gamma-cyclodextrin) glucose monomers units in a ring, creating a cone shape where the interior is hydrophobic and the exterior is hydrophilic.
- the hydrophobic cavity provides an environment into which non-polar compounds, e.g. non-polar amino acids can be included and form complexes.
- WO2010057107 describes using cyclodextrins (CDs) for reducing aggregation under physiological conditions. Furthermore, cyclodextrins and its derivatives have been used as solubilizers for poorly water soluble drugs.
- CDs cyclodextrins
- Currently available drug products that contain cyclodextrin in liquid formulations include SporanoxTM (Janssen, Belgium), Prostavasin (Ono, Japan; Schwarz, Germany), Prostandin 500 (Ono, Japan), GeodonTM (Pfizer, USA), VFENDTM (Pfizer, USA), MitoExtra MitozytrexTM (Novartis, Switzerland), and Voltaren OpthaTM (Novartis, Switzerland) (Szejtli J., Pure Appl. Chem.
- the formulation composition will additionally affect this behavior and also influence other properties, including viscosity and osmolality. Altered interactions between the excipients and the active ingredients in the formulation may affect its long term stability. This is particularly relevant for antibody formulations developed for subcutaneous administration, where a high protein concentration meets a lower administration volume and protein aggregation and precipitation become even more apparent and potentially responsible for injection side effects.
- the present invention addresses the above-identified need by providing a novel liquid formulation comprising an antibody or an antigen-binding fragment as active ingredient.
- a synergistic stabilizing effect has now been surprisingly observed between stabilizers with respect to the appearance of aggregates (precipitates) in a liquid pharmaceutical formulation.
- the invention provides for a liquid pharmaceutical formulation comprising an antibody or an antigen-binding fragment thereof, as an active ingredient, cyclodextrin and methionine.
- the liquid pharmaceutical formulation comprises methionine at a concentration of from 7.5 mM to 200 mM.
- liquid pharmaceutical formulation according to the first aspect and embodiment comprises cyclodextrin at a concentration of from 7.5 mM to 250 mM.
- the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody or an antigen-binding fragment thereof at a concentration of from 1 to 200 mg/ml, preferably from 90 to 180 mg/ml.
- the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody or an antigen-binding fragment thereof which specifically binds to human sclerostin and/or is a human or humanized antibody.
- liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody which is romosozumab.
- liquid formulation according to the first aspect and its embodiments has pH of from 4.0 to 7.5.
- the liquid formulation according to the first aspect and its embodiments comprises a cyclodextrin selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- cyclodextrin-containing polymers or combinations thereof Preferably, the cyclodextrin is selected from hydroxypropyl-gamma-cyclodextrin.
- the liquid formulation according to the first aspect and its embodiments comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006% polysorbate 20, from 55 mM to 80 mM hydroxypropyl-gamma-cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; preferably form 90 mg/ml to 180 mg/ml, more preferably from 120 mg/ml to 180 mg/ml of romosozumab.
- the present invention provides for the liquid formulation according to the first aspect and its embodiments for use in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- the present invention provides for the use of the liquid formulation according to the first aspect and its embodiments in the manufacture of a medicament for the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- the present invention provides for a method for treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength in a mammalian subject comprising administering a therapeutically effective amount of the formulation according to the first aspect and its embodiments.
- the bone disorder is osteoporosis.
- the invention provides for a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation, the method comprising providing a liquid formulation and adding to the formulation methionine and cyclodextrin, preferably hydroxylpropyl-gamma-cyclodextrin.
- the present invention provides for a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of the formulation according to the first aspect and its embodiments.
- FIG. 1 shows the sequence of the light chain of romosozumab (SEQ ID NO: 11).
- the amino acid sequence is presented using three-letter symbols with the corresponding one-letter symbol beneath each amino acid.
- Intrachain disulfide bonds are indicated by lines between linked cysteines. Cysteines forming interchain bonds are indicated in boxes.
- FIG. 2 shows the sequence of the heavy chain of romosozumab (SEQ ID NO: 12).
- the amino acid sequence is presented using three-letter symbols with the corresponding one-letter symbol beneath each amino acid.
- Intrachain disulfide bonds are indicated by lines between linked cysteines. Cysteines forming interchain bonds are indicated in boxes.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of two stabilizers, methionine and cyclodextrin.
- the synergistic combination of methionine and cyclodextrin provides the additional advantages of reducing the rate of precipitation of the antibody or the antigen-binding fragment thereof in the form of aggregates over time thus potentially reducing the occurrence of injection side reactions. Therefore, the present invention also provides for a method for reducing precipitation of an antibody or antigen-binding fragment thereof in a liquid pharmaceutical formulation, the method comprising providing a liquid formulation and adding to the formulation methionine and cyclodextrin.
- the concentration of cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 25 0mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- the concentration of methionine in the liquid pharmaceutical formulation may be from 7.5 mM to 200 mM or from 15 mM to 200 mM or from 30 mM to 200 mM or from 55 mM to 160 mM or preferably from 55 mM to 125 mM.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of cyclodextrin to methionine.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of cyclodextrin.
- the cyclodextrin may be selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- cyclodextrins The most common natural cyclodextrins are alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin, all of which are hydrophilic. Substitutions of the hydroxyl groups further enhance the cyclodextrin solubility (Loftsson T. et al, Expert Opin. Drug Deliv. 2, 335-351 (2005); Davis M.E. & Brewster M.E., Nature Reviews — Drug discovery 3, 1023-1035 (2004)).
- cyclodextrins of interest are mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of methionine and a chemically modified cyclodextrin, preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the concentration of the chemically modified cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 250 mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of chemically modified cyclodextrin to methionine.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of a chemically modified cyclodextrin.
- the preferred cyclodextrin according to the present invention is hydroxypropyl-gamma-cyclodextrin such as 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin, 2,3-dihydroxypropyl-gamma-cyclodextrin or combinations thereof.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of methionine and hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin, 2,3-dihydroxypropyl-beta-cyclodextrin or combinations thereof).
- methionine and hydroxypropyl-beta-cyclodextrin i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin, 2,3-dihydroxypropyl-beta-cyclodextrin or combinations thereof.
- the concentration of hydroxypropyl-gamma-cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 250 mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of hydroxypropyl-gamma-cyclodextrin to methionine.
- the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of hydroxypropyl-gamma-cyclodextrin.
- the concentration of antibody or antigen-binding fragment thereof in the liquid formulation according to the present invention may be from 1 to 200 mg/ml, or from to 200 mg/ml, or from to 200mg/ml or preferably from 90 to 180 mg/ml.
- the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of cyclodextrin.
- the cyclodextrin may be selected from beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of a chemically modified cyclodextrin, preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of hydroxypropyl-gamma-cyclodextrin such as 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin, 2,3-dihydroxypropyl-gamma-cyclodextrin or combinations thereof.
- hydroxypropyl-gamma-cyclodextrin such as 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin, 2,3-dihydroxypropyl-gamma-cyclodextrin or combinations thereof.
- the active ingredient comprised in the liquid pharmaceutical formulation according to the invention is preferably an antibody.
- the antibody has an isoelectric point (pl) lower than the physiological pH ( ⁇ 7.0) but higher than the formulation pH.
- the liquid formulation according to the present invention and its embodiments comprises from 1 to 200 mg/ml of an antibody, wherein the antibody has a pl of from 5.0 to 6.9, preferably from 5.3 to 6.9.
- the antibody comprised in the liquid pharmaceutical formulation according to the invention specifically binds to human sclerostin.
- the term “specifically binds to human sclerostin”, “specifically binding to human sclerostin”, and equivalents as used herein when referring to an antibody means the antibody will bind to human sclerostin with sufficient affinity and specificity to achieve a biologically meaningful effect.
- the antibody selected will normally have a binding affinity for human sclerostin, for example, the antibody may bind human sclerostin with a Kd value of between 100 nM and 1 pM.
- Antibody affinities may be determined by a surface plasmon resonance bases assay, such as the BlAcore assay; enzyme-linked immunoabsorbent assay (ELISA); and competition assays (e.g. RIA's), for example.
- an antibody specifically binding to human sclerostin may also bind to another molecule, e.g. mouse sclerostin or such as by way of a non-limiting example in the case of a bispecific antibody.
- Sclerostin a protein encoded by the SOST gene, is a glycoprotein secreted by osteocytes and is a potent inhibitor of osteoblastogenesis.
- Loss-of-function mutations in SOST are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth.
- a deletion downstream of the SOST gene, which results in reduced sclerostin expression, is associated with a milder form of the disease called van Buchem disease.
- SOST-null mice have a high-bone-mass phenotype.
- the antibody or antigen-binding fragment thereof binding specifically to human sclerostin preferably also neutralizes human sclerostin.
- neutralizes refers to an antibody that inhibits or substantially reduces the biological effect of the molecule to which it specifically binds. Therefore, the expression “the antibody neutralizes human sclerostin” refers to an antibody that specifically binds to human sclerostin and inhibits or substantially reduces the biological effect thereof.
- antibody refers to monoclonal or polyclonal antibodies.
- antibody or “antibodies” as used herein includes but is not limited to recombinant antibodies that are generated by recombinant technologies as known in the art.
- the antibody comprised in the liquid formulation according to the invention is a monoclonal antibody which specifically binds human sclerostin.
- Antibody or “antibodies” include antibodies' of any species, in particular of mammalian species, having two essentially complete heavy and two essentially complete light chains, human antibodies of any isotype, including IgA 1 , IgA 2 , IgD, IgG 1 , IgG 2a , IgG 2b , IgG 3 , IgG 4 IgE and IgM and modified variants thereof, non-human primate antibodies, e.g. from chimpanzee, baboon, rhesus or cynomolgus monkey, rodent antibodies, e.g. from mouse, rat or rabbit; goat or horse antibodies, and camelid antibodies (e.g.
- antibody or “antibodies” also refers to “chimeric” antibodies in which a first portion of at least one heavy and/or light chain antibody sequence is from a first species and a second portion of the heavy and/or light chain antibody sequence is from a second species.
- Chimeric antibodies of interest herein include “primatized” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, such as baboon, rhesus or cynomolgus monkey) and human constant region sequences.
- Humanized antibodies are chimeric antibodies that contain a sequence derived from non-human antibodies.
- humanized antibodies are human antibodies (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region [or complementarity determining region (CDR)] of a non-human species (donor antibody) such as mouse, rat, rabbit, chicken or non-human primate, having the desired specificity, affinity, and activity.
- donor antibody such as mouse, rat, rabbit, chicken or non-human primate, having the desired specificity, affinity, and activity.
- residues of the human (recipient) antibody outside of the CDR i.e. in the framework region (FR)
- humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody.
- Humanization reduces the immunogenicity of non-human antibodies in humans, thus facilitating the application of antibodies to the treatment of human diseases.
- Humanized antibodies and several different technologies to generate them are well known in the art.
- the term “antibody” or “antibodies” also refers to human antibodies, which can be generated as an alternative to humanization.
- transgenic animals e.g., mice
- JH antibody heavy-chain joining region
- the antibody effector functions in the immune system of the transgenic mouse and consequently the B cell development are essentially unchanged, which may lead to an improved antibody response upon antigenic challenge in vivo.
- the genes coding for a particular antibody of interest have been isolated from such transgenic animals the genes coding for the constant regions can be replaced with human constant region genes in order to obtain a fully human antibody.
- the term “antibody” or “antibodies” as used herein, also refers to an aglycosylated antibody.
- antibody fragment refers to an antibody fragment.
- a fragment of an antibody comprises at least one heavy or light chain immunoglobulin domain as known in the art and binds to one or more antigen(s).
- antibody fragments according to the invention include Fab, Fab′, F(ab′) 2 , and Fv and scFv fragments; as well as diabodies, triabodies, tetrabodies, minibodies, domain antibodies(dAbs), such as sdAbs, VHH and VNAR fragments, single-chain antibodies, bispecific, trispecific, tetraspecific or multispecific antibodies formed from antibody fragments or antibodies, including but not limited to Fab-Fv or Fab-Fv-Fv constructs.
- Antibody fragments as defined above are known in the art.
- the antibody or antigen-binding fragment thereof comprised as active ingredient in the liquid pharmaceutical formulation according to the invention may be human or humanized antibody, preferably a humanized monoclonal antibody which specifically binds human sclerostin.
- CDR complementarity determining regions
- the antibody comprised as active ingredient in the liquid pharmaceutical formulation according to the invention is romosozumab, an anti-human sclerostin antibody as described in WO2006119107 and WO2011143307 (incorporated herein by reference).
- the present invention also provides for a liquid pharmaceutical formulation comprising romosozumab and a cyclodextrin, preferably selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention may contain a buffering agent to maintain a constant pH during storage and administration.
- buffering agents used in the field of liquid pharmaceutical formulations, such as, but not limited to, citrate, phosphate, lactate, histidine, glutamate, maleate, tartrate, or succinate.
- a preferred buffer species is typically selected amongst those having a pKa that is close ( ⁇ 1 pH unit) to the preferred pH for optimal protein stability in order to maintain high buffering capacity, and is associated with the maximal demonstrated stability observed for a particular protein when placed in a series of varied buffer species.
- the adequate pH ranges of a formulation are generally chosen from those associated with the maximal demonstrated stability observed for a particular protein when placed in a series of varied pH formulations.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises sodium acetate, preferably at a concentration of 10 mM to 100 mM, 10 mM to 80 mM, 10 mM to 60 mM, 25 mM to 60 mM, preferably 40 mM to 60 mM, or 50 mM.
- the liquid pharmaceutical formulation according to the invention may also comprise calcium acetate, preferably at a concentration of 0.5 mM to 50 mM, 5 mM to 40 mM, 10 mM to 30 mM or 14 mM. More preferably, the liquid pharmaceutical formulation according to the invention comprises 50 mM sodium acetate and 14 mM calcium acetate.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention may have a pH of 4 to 7.5, preferably 4 to 6, preferably 4.5 to 5.5, or 5.2.
- liquid pharmaceutical formulation according to any of the embodiments of the invention additionally comprises a surfactant.
- a surfactant available for use in the liquid formulation according to any of the embodiments of the invention such as but not limited to polysorbate 80, polysorbate 20, lecithin, poloxamer (e.g.
- poloxamer 188 sodium dodecyl sulfate (SDS), sodium laurel sulfate, sodium octyl glycoside, lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine, lauryl-, myristyl-, linoleyl- or stearyl-sarcosine, linoleyl-, myristyl-, or cetyl-betaine, lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine, sodium methyl cocoyl-, or disodium methyl oleyl-taurate,
- the liquid formulation of the invention may comprise from 0.001% to 10% Polysorbate 20, from 0.001% to 5% Polysorbate 20, from 0.001 to 1% Polysorbate 20, from 0.001 to 0.006% Polysorbate 20, or 0.006% Polysorbate 20.
- the liquid formulation according to the embodiments of the invention may further comprise additional excipients commonly used in the preparation of liquid pharmaceutical formulations including but not limited to sugars (e.g. sucrose or treahalose), poly-ethylene glycols (e.g. PEG100, PEG300, PEG600, PEG1500, PEG2000, PEG3000, PEG3350, PEG4000, PEG6000, PEG8000 or PEG20000), polyols (e.g. mannitol, sorbitol or lactitol), other amino acids than methionine, polyvinylpyrrolidone, trimethylamine N-oxide, trimethylglycine or combinations thereof.
- sugars e.g. sucrose or treahalose
- poly-ethylene glycols e.g. PEG100, PEG300, PEG600, PEG1500, PEG2000, PEG3000, PEG3350, PEG4000, PEG6000, PEG8000 or PEG20000
- liquid formulation according to the embodiments of the invention may further comprise sucrose, from 0 to 6% sucrose, more preferably 6% sucrose.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006% polysorbate 20, from 55 mM to 80 mM of a chemically modified cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; more preferably form 90 mg/ml to 180 mg/ml and even more preferably from 120 mg/ml to 180 mg/ml of antibody, wherein the chemically modified cyclodextrin is preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006% polysorbate 20, from 55 mM to 80 mM hydroxypropyl-gamma-cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; more preferably form 90 mg/ml to 180 mg/ml and even more preferably from 120 mg/ml to 180 mg/ml of antibody.
- the liquid pharmaceutical formulation according to the invention comprises at least 90 mg/ml antibody, 55 mM hydroxypropyl-gamma-cyclodextrin, 125 mM methionine 55 mM sodium acetate buffer at pH 5, 14 mM calcium acetate, 6% sucrose and 0.006% polysorbate 20, wherein the antibody is an anti-human sclerostin antibody.
- the liquid pharmaceutical formulation according to the invention comprises at least 90 mg/ml antibody, 55 mM hydroxypropyl-gamma-cyclodextrin, 125 mM methionine 55 mM sodium acetate buffer at pH 5, 14 mM calcium acetate, 6% sucrose and 0.006% polysorbate 20, wherein the antibody is an anti-human sclerostin antibody and the formulation is for subcutaneous administration.
- liquid pharmaceutical formulation according to any of the embodiments of the invention exhibits an osmolality of 800 mOsm/l or less and/or a viscosity of 80 cP or less.
- the liquid formulation is not a hydrogel. In an embodiment the liquid formulation comprises at least 2%, at least 5%, at least 10%, at least 25%, between 2% and 90%, between 2% and 75%, or between 2% and 50% water.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- the invention provides for a method of treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strengthin a mammalian subject comprising administering a therapeutically effective amount of the liquid pharmaceutical formulation according to any of the embodiments of the invention.
- the invention provides for the use of the liquid formulation according to any one of the embodiments of the invention for the manufacture of a medicament for the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- the mammalian subject may be selected from the group of rodents, cats, dogs, horses, bovine, ovine, non-human primates and human subjects.
- the mammalian subject is a human subject.
- the invention is typically used to treat or help prevent a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- the bone disorder is characterized by an altered function of sclerostin or by an increased/decreased expression of sclerostin protein in relevant tissue (e.g. bone, cartilage).
- relevant tissue e.g. bone, cartilage
- the invention may be, for example, employed to increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength.
- the bone disorder may be associated with abnormal osteoblast or osteoclast activity, with decreased bone density, increased bone resorption and/or bone-related disorders, i.e. osteoporosis.
- the bone disorder may be selected from the group of achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's Disease, hypophosphatemia rickets, Marfan's syndrome, multiple hereditary exotoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, pseudoarthrosis, pyogenic osteomyelitis, periodontal disease, anti-epileptic drug induced bone loss, primary and secondary hyperparathyroidism, familial hyperparathyroidism syndromes, weightlessness induced bone loss, osteoporosis in men, postmenopausal bone loss, osteoarthritis, renal osteodystrophy, infiltrative disorders of bone, oral bone loss
- Klinefelter Syndrome leprosy, Perthes' Disease, adolescent idiopathic scoliosis, infantile onset multi-system inflammatory disease, Winchester Syndrome, Menkes Disease, Wilson's Disease, ischemic bone disease (such as Legg-Calve-Perthes disease, regional migratory osteoporosis), anemic states, conditions caused by steroids, glucocorticoid-induced bone loss, heparin-induced bone loss, bone marrow disorders, scurvy, malnutrition, calcium deficiency, osteoporosis, osteopenia, alcoholism, chronic liver disease, postmenopausal state, chronic inflammatory conditions, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, inflammatory colitis, Crohn's disease, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, thyroid disorders, parathyroid disorders, Cushing's disease, acromega
- Bone loss, decreased bone mineral density, decreased bone volume, and/or decreased bone mineral content associated with these disorders may be treated in the context of the invention.
- the subject to be treated may be pregnant.
- the invention may be employed to help in pregnancy-related bone loss.
- the invention may be used to slow, or reverse, bone loss in general.
- the bone disorder to be treated is osteoporosis or osteopenia.
- the mammalian subject to be treated is a postmenopausal woman, for instance, one with osteoporosis, particularly such a subject who is at increased, or high risk, for fracture, or has failed or is intolerant to other available osteoporosis therapy.
- the invention may be employed in improving the outcome in a mammal undergoing one or more of an orthopedic procedure, dental procedure, implant surgery, joint replacement, bone grafting, bone cosmetic surgery and bone repair such as fracture healing, nonunion healing, delayed union healing and facial reconstruction.
- the subject has, or is thought at risk of, a bone fracture.
- a bone fracture For instance, it may be that the subject has a bone mineral density that identifies them at risk of bone fracture. It may be that the subject has recently been diagnosed with a bone disorder as a result of a bone fracture. In some instances, it may be that the subject has a fracture of the wrist, arm, leg, hip or vertebrae and in some cases it may be that the fracture has resulted in the diagnosis of the bone disorder.
- the bone disorder is selected from osteoporosis, bone gap defect, alveolar bone loss, inhibited bone resorption or combinations thereof.
- the present invention also provides for a method for reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of the liquid pharmaceutical formulation according to any of the embodiments of the invention.
- the liquid pharmaceutical formulations according to the invention are administered in a therapeutically effective amount.
- therapeutically effective amount refers to an amount of a therapeutic agent (i.e. active ingredient) needed to treat, ameliorate or prevent a targeted disease, disorder or condition, or to exhibit a detectable therapeutic, pharmacological or preventative effect.
- the therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- a therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, a therapeutically effective amount of antibody will be from 0.01 mg/kg to 500 mg/kg, for example 0.1 mg/kg to 200 mg/kg, such as 100 mg/kg.
- the liquid pharmaceutical formulation may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose.
- the appropriate dosage will vary depending upon, for example, the particular antibody to be employed, the subject treated, the mode of administration and the nature and severity of the condition being treated.
- the liquid pharmaceutical formulation of the invention is administered by intravenous or subcutaneous route. When administered via intravenous injection, it may be administered as a bolus injection or as a continuous infusion.
- the liquid pharmaceutical formulation according to any of the embodiments of the invention may also be administered by intramuscular injection.
- the liquid pharmaceutical formulation may be injected using a syringe, an injection device such as an autoinjector, a needleless device, an implant and a patch.
- the liquid pharmaceutical formulation of the invention may also be administered via inhalation using an inhalation device containing said formulation for such delivery, for example using a nebulizer or liquid inhaler.
- liquid pharmaceutical formulation of the invention is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards; it may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the conditions as described herein before.
- the antibody or antigen-binding fragment thereof may be the sole active ingredient in the liquid pharmaceutical formulation. Alternatively, the antibody or antigen-binding fragment thereof may be administered in combination, e.g. simultaneously, sequentially or separately, with one or more other therapeutically active ingredients. Active ingredient as employed herein refers to an ingredient with a pharmacological effect, such as a therapeutic effect, at a relevant dose. In some embodiments the antibody or antigen-binding fragment thereof in the liquid pharmaceutical formulation may be accompanied by other active ingredients including other antibodies or non-antibody ingredients.
- the antibody in the liquid pharmaceutical formulation according to the invention is an anti-sclerostin antibody
- the subject may be administered with an additional active ingredient to treat their bone disorder.
- the subject may be, for instance, treated with any other therapy for treating bone disorders.
- the subject is administered an anti-resorptive, in a particularly preferred instance the additional agent is administered at a time when the subject is not being treated with the liquid pharmaceutical formulation according to the invention and its embodiments.
- such an additional active ingredient may be administered at the same time or overlapping with the administration of the liquid pharmaceutical formulation according to the invention.
- the additional agent may be, for instance, vitamin D.
- the other therapeutic active ingredient may be a bone resorption inhibitor.
- the bone resorption inhibitor is a bisphosphonate, particularly a nitrogen containing bisphosphonate.
- bisphosphonates examples include, but are not limited to, Alendronate, bonefos ciodronate, etidronate, ibandronic acid, olpadronate, neridronate, risedronate sodium, skelid, and zoledronic acid.
- the bisphosphonate is zoledronic acid.
- Bisphosphonates which may be employed include, for instance, ActonelTM, AclastaTM/ReclastTM, BonivaTM/BonvivaTM, FosamaxTM, and ZometaTM.
- the additional active ingredient is an anti-resorptive and even more preferably is Alendronate.
- Selected estrogen receptor modulators may also be employed as bone resorption inhibitors, for instance, arzoxifene, apeledoxifene, FC 1271, lasofoxifene, raloxifene, and Tibolone are examples of suitable SERMs.
- Other bone resorption inhibitors which may be used include estrogen and calcitonin, with examples of calcitonin including salmon calcitonins, such as MiacalcinTM.
- Strontium compounds in particular strontium ranelate, or PTH, in particular recombinant parathyroid hormone releasing peptide, parathyroid hormone or analogs thereof (e.g., teriparatide (FORTEO®), may also be employed as the bone resorption inhibitor.
- PTH in particular recombinant parathyroid hormone releasing peptide, parathyroid hormone or analogs thereof (e.g., teriparatide (FORTEO®)
- FRTEO® teriparatide
- the bone resorption inhibitor is a RANKL inhibitor, such as an anti-RANKL antibody.
- the bone resorption inhibitor employed may be denosumab.
- the anti-resorptive employed is not a bisphosphonate.
- agents which may be employed include PROLIA®, calcitonin, and cathepsin K inhibitors (e.g., odanacatib).
- a bone resorption inhibitor may be administered at the same time, or approximately the same time, as the antibody, or so the two therapies overlap. It may be that the bone resorption inhibitor is given to help prolong further the effect of the anti-sclerostin antibody by reducing the breakdown of bone that the antibody has stimulated and in particular where the compound is a bisphosphonate. In one preferred instance, there is no overlap in the treatment of the subject with anti-sclerostin antibody and the further treatment for the bone disorder, for instance the two treatments are alternated, but never overlap.
- Antibody molecules may be typically produced by culturing a host cell containing a vector encoding the antibody sequence under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.
- the antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host cells.
- the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide.
- a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.
- An antibody or an antigen-binding fragment thereof that can be manufactured according to industrial scales can be produced by culturing eukaryotic host cells transfected with one or more expression vectors encoding the recombinant antibody fragment.
- the eukaryotic host cells are preferably mammalian cells, more preferably Chinese Hamster Ovary (CHO) cells.
- Mammalian cells may be cultured in any medium that will support their growth and expression of the recombinant protein, preferably the medium is a chemically defined medium that is free of animal-derived products such as animal serum and peptone.
- the medium is a chemically defined medium that is free of animal-derived products such as animal serum and peptone.
- cell culture mediums available to the person skilled in the art comprising different combinations of vitamins, amino acids, hormones, growth factors, ions, buffers, nucleosides, glucose or an equivalent energy source, present at appropriate concentrations to enable cell growth and protein production.
- Additional cell culture media components may be included in the cell culture medium at appropriate concentrations at different times during a cell culture cycle that would be known to those skilled in the art.
- Mammalian cell culture can take place in any suitable container such as a shake flask or a bioreactor, which may or may not be operated in a fed-batch mode depending on the scale of production required. These bioreactors may be either stirred-tank or air-lift reactors. Various large scale bioreactors are available with a capacity of more than 1,000 L to 50,000 L, preferably between 5,000 L and 20,000 L, or to 10,000 L. Alternatively, bioreactors of a smaller scale such as between 2 L and 100 L may also be used to manufacture an antibody or antibody fragment.
- An antibody or antigen-binding fragment thereof is typically found in the supernatant of a mammalian host cell culture, typically a CHO cell culture.
- a mammalian host cell culture typically a CHO cell culture.
- the protein of interest such as an antibody or antigen-binding fragment thereof is secreted in the supernatant
- said supernatant is collected by methods known in the art, typically by centrifugation.
- the antibody or antigen-binding fragment thereof production method comprises a step of centrifugation and supernatant recovery after cell culture and prior to protein purification.
- said centrifugation is continuous centrifugation.
- supernatant denotes the liquid lying above the sedimented cells resulting from the centrifugation of the cell culture.
- host cells are prokaryotic cells, preferably gram-negative bacteria. More preferably, the host cells are E. coli cells. Prokaryotic host cells for protein expression are well known in the art (Terpe, K. Appl Microbiol Biotechnol 72, 211-222 (2006)). The host cells are recombinant cells which have been genetically engineered to produce the protein of interest such as an antigen-binding fragment of an antibody.
- the recombinant E. coli host cells may be derived from any suitable E. coli strain including from MC4100, TG1, TG2, DHB4, DH5a, DH1, BL21, K12, XL1Blue and JM109.
- E. coli strain including from MC4100, TG1, TG2, DHB4, DH5a, DH1, BL21, K12, XL1Blue and JM109.
- E. coli strain including from MC4100, TG1, TG2, DHB4, DH5a, DH1, BL
- Antibody fragments can also be produced by culturing modified E. coli strains, for example metabolic mutants or protease deficient E. coli strains.
- An antibody fragment is typically found in either the periplasm of the E. coli host cell or in the host cell culture supernatant, depending on the nature of the protein, the scale of production and the E. coli strain used.
- the methods for targeting proteins to these compartments are well known in the art (Makrides, S. C.; Microbiol Rev 60, 512-538 (1996)).
- suitable signal sequences to direct proteins to the periplasm of E. coli include the E. coli PhoA, OmpA, OmpT, LamB and OmpF signal sequences.
- Proteins may be targeted to the supernatant by relying on the natural secretory pathways or by the induction of limited leakage of the outer membrane to cause protein secretion examples of which are the use of the pelB leader, the protein A leader, the co-expression of bacteriocin release protein, the mitomycin-induced bacteriocin release protein along with the addition of glycine to the culture medium and the co-expression of the kil gene for membrane permeabilization.
- the recombinant protein is expressed in the periplasm of the host E. coll.
- Expression of the recombinant protein in the E. coli host cells may also be under the control of an inducible system, whereby the expression of the recombinant antibody in E. coli is under the control of an inducible promoter.
- inducible promoters suitable for use in E. coli are well known in the art and depending on the promoter expression of the recombinant protein can be induced by varying factors such as temperature or the concentration of a particular substance in the growth medium.
- inducible promoters examples include the E.coli lac, tac, and trc promoters which are inducible with lactose or the non-hydrolyzable lactose analog, isopropyl-b-D-1-thiogalactopyranoside (IPTG) and the phoA, trp and araBAD promoters which are induced by phosphate, tryptophan and L-arabinose respectively. Expression may be induced by, for example, the addition of an inducer or a change in temperature where induction is temperature dependent.
- induction of recombinant protein expression is achieved by the addition of an inducer to the culture
- the inducer may be added by any suitable method depending on the fermentation system and the inducer, for example, by single or multiple shot additions or by a gradual addition of inducer through a feed. It will be appreciated that there may be a delay between the addition of the inducer and the actual induction of protein expression for example where the inducer is lactose there may be a delay before induction of protein expression occurs while any pre-existing carbon source is utilized before lactose.
- E. coli host cell cultures may be cultured in any medium that will support the growth of E. coli and expression of the recombinant protein.
- the medium may be any chemically defined medium such as e.g. described in Durany O, et al. (2004). Studies on the expression of recombinant fuculose-1-phosphate aldolase in Escherichia coli . Process Biochem 39, 1677-1684.
- Culturing of the E. coli host cells can take place in any suitable container such as a shake flask or a fermenter depending on the scale of production required.
- Various large scale fermenters are available with a capacity of more than 1,000 liters up to about 100,000 liters.
- fermenters of 1,000 to 50,000 liters are used, more preferably 1,000 to 25,000, 20,000, 15,000, 12,000 or 10,000 liters.
- Smaller scale fermenters may also be used with a capacity of between 0.5 and 1,000 liters.
- Fermentation of E. coli may be performed in any suitable system, for example continuous, batch or fed-batch mode depending on the protein and the yields required. Batch mode may be used with shot additions of nutrients or inducers where required. Alternatively, a fed-batch culture may be used and the cultures grown in batch mode pre-induction at the maximum specific growth rate that can be sustained using the nutrients initially present in the fermenter and one or more nutrient feed regimes used to control the growth rate until fermentation is complete. Fed-batch mode may also be used pre-induction to control the metabolism of the E. coli host cells and to allow higher cell densities to be reached.
- the host cells may be subject to collection from the fermentation medium, e.g. host cells may be collected from the sample by centrifugation, filtration or by concentration.
- the process typically comprises a step of centrifugation and cell recovery prior to extracting the protein.
- the production process comprises an additional protein extraction step prior to protein purification.
- Stability and propensity to precipitate within a formulation is greatly affected by the concentration (steric crowding) and the excipients used within the formulation to control the interactions observed due to steric crowding.
- the pH shift model is designed to replicate the pH shift that occurs when a formulation comprising a drug is administered by subcutaneous injection (Elena Garcia-Fruitos, Insoluble Proteins: Methods and Protocols, Methods in Molecular Biology, vol. 1258, Chapter 18:321-330, Springer Science+Business Media New York (2015)).
- Biotherapeutic proteins, in particular antibodies, are often formulated below physiological pH ( ⁇ pH7.0). If the pl of the protein is less than pH 7.0 but higher than the formulation pH, the protein will shift through its pl. This will reduce the solubility of the protein and cause it to precipitate.
- This model is designed to replicate this pH shift and aid in assessing formulations' suitability for subcutaneous injection.
- a tissue buffer (10 mM Sodium Bicarbonate and 150 mM Sodium Chloride) is prepared the day before and placed into the CO2 incubator at 37° C./7% CO 2 on a gentle stir overnight to equilibrate.
- About 0.5 mL of each test sample is loaded into a slide-a-lyser cassette according to the manufacturer 'instructions (Thermo Scientific, Slide-A-Lyzer Dialysis Cassettes G2, Prod#87727, 7000 MWCO, 0.5 mL).
- the slide-a-lyser cassettes are gently placed into the equilibrated tissue buffer within the CO 2 incubator and left overnight.
- the slide-a-lyser cassettes are visually assessed against a white and black background for signs of precipitation every hour for the first 4-6 hours and then after 24 hours (or longer).
- Romosozumab at 120 mg/mL in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006% polysorbate 20 at pH 5.2 were prepared by performing a 1:1 serial dilution.
- An initial solution was prepared by adding 881 mg of HPGCD to 2 ml of romosozumab at 120 mg/mL in DS to give a final HPGCD concentration of 250 mM.
- Half of this solution (1 mL) was mixed 1:1 with the same volume of romosozumab at 120 mg/mL in DS to achieve a sample of romosozumab at 120 mg/mL in DS with 125 mM HPGCD.
- the formulations comprising 0 to 250 mM concentrations of HPGCD were buffer exchanged and concentrated using 30 kDa Sartorius Viva Spin centrifugal spin filters of varying volumes (2-20 mL). The spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes. Samples were mixed between spin cycles using a positive displacement pipette volume exchange.
- the concentration of each sample was measured in duplicate before and after dialysis (Table 2) using the C Technologies Solo VPE high concentration UV spectrophotometer linked to a Cary 50 spectrophotometer. Concentration was determined by absorbance at A280. Result reported as mean of duplicate sample readings.
- the pH was determined using the Hach H260G pH meter and ISFET solid state probe. All samples were stored at 5° C. after preparation.
- Romosozumab in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to 125 mg/mL or to 190 mg/mL using 30 kDa Sartorius Viva Spin centrifugal spin filters.
- the spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes; samples were mixed between spin cycles using a positive displacement pipette.
- the required amount of methionine to produce 2.2 mL of sample with the required concentration (55 and 200 mM) was weighed (0.018 g and 0.0066 g, respectively) using an analytical balance. Methionine was dissolved in 2.2 mL of the appropriate protein solution (125 mg/mL or 190 mg/mL).
- Romosozumab in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to 125 mg/mL or to 190 mg/mL using 30kDa Sartorius Viva Spin centrifugal spin filters.
- the spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes; samples were mixed between spin cycles using a positive displacement pipette.
- the required amount of methionine to produce 2.2 mL of sample with the required concentration (55 and 200 mM) was weighed (0.018 g and 0.066 g, respectively) using an analytical balance.
- the Methionine was dissolved in 2.2 mL of the appropriate protein solution (125 mg/mL or 190 mg/mL).
- the required amount of HPGCD to produce 1 mL of 30 mM HPGCD at the required concentration was weighed (0.053 g) using an analytical balance. 1 ml of the appropriate protein/methionine solution was used to dissolve the HPGCD.
- HPGCD and methionine improved the rate of precipitation over the basic formulation, especially at high concentrations of romosozumab (180 mg/mL).
- Romosozumab at 120 mg/mL in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to ⁇ 190 mg/mL using 30 kDa Sartorius Viva Flow 50, bench scale tangential flow filtration (TFF) cartridge. System was run using a Masterflex peristaltic pump at a pressure of ⁇ 2.5 Bar, ⁇ 6x volume exchange.
- Romosozumab at 120 mg/mL in DS was buffer exchanged to 55 mM sodium acetate, 6% sucrose, 0.006% polysorbate 20, pH5.2 (without calcium acetate) and concentrated to ⁇ 190 mg/mL using 30 kDa Sartorius Viva Flow 50, bench scale tangential flow filtration (TFF) cartridge. System was run using a Masterflex peristaltic pump at a pressure of ⁇ 2.5 Bar, ⁇ 6x volume exchange.
- Methionine and HPGCD were spiked according to the experiment design (Table 10).
- the required amount of Methionine to produce 1.2 mL of sample with the required concentration was weighed using an analytical balance.
- the Methionine was dissolved in 2.2 mL of the appropriate protein solution (with/without calcium acetate).
- the required amount of HPGCD to produce 1 mL of sample at the required concentration was weighed using an analytical balance. 1 ml of the appropriate protein/methionine solution (with/without calcium acetate) was used to dissolve the HPGCD.
- A150 means formulation A as of Table 12 with 150 mg/mL of romosozumab
- A180 means formulation A as of Table 13 with 180 mg/mL of romosozumab etc.
- Control formulations comprise the basic formulation of 55 mM sodium acetate, 14mM calcium acetate, 6% sucrose, 0.006% polysorbate 20, 96 mM HPGCD, pH 5.2 at concentration of romosozumab of 90 mg/mL, 120 mg/mL, 150 mg/mL and 180 mg/mL.
- HPGCD HPGCD
- methionine has been found to be surprisingly beneficial for stabilizing antibodies, especially at high concentrations, in liquid formulations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-bindmg fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis. Furthermore, the invention relates to a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclo dextrin and methionine.
Description
- The present invention belongs to the field of pharmaceutical formulations. More specifically, it relates to a pharmaceutical formulation comprising an antibody, cyclodextrin and methionine.
- This application contains, as a separate part of the disclosure, a Sequence Listing in computer readable form (Filename: 58045B_SeqListing.xml; Size: 17,137 bytes; Created Jan. 10, 2023), which is incorporated by reference in its entirety.
- Antibodies are large and complex molecules and are inherently chemically and physically instable when stored over a period of time at high concentration. Typical chemical instability may result in deamidation, hydrolysis, oxidation, beta-elimination or disulfide exchanges. Physical instability can result in denaturation, aggregation or precipitation.
- Antibodies can be formulated in freeze-dried, i.e. lyophilized form for reconstitution in a solvent shortly before administration. Freeze-dried formulations of antibodies tend to be more stable than liquid water-based formulation as water is either a reactant or facilitates the transfer of reactants and is thus critical to chemical degradation and protein instability. Despite being less stable, interest has recently focused on liquid formulations of antibodies. These formulations are easier and more convenient for the patient and the healthcare professional to handle and administer in comparison to freeze-dried formulations. Liquid formulations do not need to be reconstituted and can be administered with minimal preparation. However, the stabilization of proteins in liquid formulations to avoid or minimize aggregation, precipitation or degradation remains a particular challenge. Aggregation, with the formation of insoluble matter or precipitate, is a particular problem. This may cause various problems. Firstly aggregate formation may result in the antibody being less or no longer active; aggregate may provoke undesired and unexpected immunological reactions upon administration and finally aggregates may prevent proper administration of the pharmaceutical formulation e.g. by blocking syringes or pumps. These problems are even more evident in liquid formulations for subcutaneous administration where antibodies are present at high concentrations in much smaller volumes than intravenous infusions.
- A typical strategy for preventing aggregation is to add stabilizers to the antibody formulation. Commonly used stabilizers include sugars, salts, free amino acids, polyols, polyethylene glycols (PEGs), and other polymers, such as polysorbates or poloxamers that may reduce protein-protein interactions.
- Cyclodextrins (sometimes called cycloamyloses) are a family of compounds made up of sugar molecules bound together in a ring (cyclic oligosaccharides). Cyclodextrins are produced from starch by means of enzymatic conversion. They are considered safe and are widely used in food, pharmaceutical drug delivery, and chemical industries, as well as agriculture and environmental engineering. Cyclodextrins are composed of 5 or more α-D-glucopyranoside units linked 1->4, as in amylose. Typical cyclodextrins contain 6 (alpha-cyclodextrin), 7 (beta-cyclodextrin) or 8 (gamma-cyclodextrin) glucose monomers units in a ring, creating a cone shape where the interior is hydrophobic and the exterior is hydrophilic. The hydrophobic cavity provides an environment into which non-polar compounds, e.g. non-polar amino acids can be included and form complexes.
- WO2010057107 describes using cyclodextrins (CDs) for reducing aggregation under physiological conditions. Furthermore, cyclodextrins and its derivatives have been used as solubilizers for poorly water soluble drugs. Currently available drug products that contain cyclodextrin in liquid formulations include Sporanox™ (Janssen, Belgium), Prostavasin (Ono, Japan; Schwarz, Germany), Prostandin 500 (Ono, Japan), Geodon™ (Pfizer, USA), VFEND™ (Pfizer, USA), MitoExtra Mitozytrex™ (Novartis, Switzerland), and Voltaren Optha™ (Novartis, Switzerland) (Szejtli J., Pure Appl. Chem. 76:1825-1845 (2004); Loftsson T. et al, Expert Opin. Drug Deliv. 2, 335-351 (2005)). Most of these formulations are for small molecule compounds. Maximum benefit is usually obtained at low cyclodextrin concentrations, and the benefits are often only partially concentration dependent. For example, aggregation of IL-2 was optimally inhibited by 0.5% HP-beta-cyclodextrin. (Loftsson T. and Brewster M. E., J Pharm Sci 85: 1017-1025 (1996)). The solubility of human growth hormone was improved by CDs present at about 2-6%, with alpha and gamma cyclodextrins found to be several-fold less effective than beta cyclodextrins. (Otzen, D. E. et al., Protein Sci. 11:1779-1787 (2002)).
- Whilst the primary sequence of an antibody define its pl and it's intrinsically responsible of its tendency to precipitate upon administration (e.g. pH shift), the formulation composition will additionally affect this behavior and also influence other properties, including viscosity and osmolality. Altered interactions between the excipients and the active ingredients in the formulation may affect its long term stability. This is particularly relevant for antibody formulations developed for subcutaneous administration, where a high protein concentration meets a lower administration volume and protein aggregation and precipitation become even more apparent and potentially responsible for injection side effects.
- Given the above, there remains a need in the art to provide further improved liquid pharmaceutical formulations of antibodies with reduced protein aggregation and precipitation, especially for formulations for subcutaneous route of administration.
- The present invention addresses the above-identified need by providing a novel liquid formulation comprising an antibody or an antigen-binding fragment as active ingredient. A synergistic stabilizing effect has now been surprisingly observed between stabilizers with respect to the appearance of aggregates (precipitates) in a liquid pharmaceutical formulation.
- Therefore, in a first aspect, the invention provides for a liquid pharmaceutical formulation comprising an antibody or an antigen-binding fragment thereof, as an active ingredient, cyclodextrin and methionine.
- In a first embodiment of this aspect the liquid pharmaceutical formulation comprises methionine at a concentration of from 7.5 mM to 200 mM.
- In a second embodiment the liquid pharmaceutical formulation according to the first aspect and embodiment comprises cyclodextrin at a concentration of from 7.5 mM to 250 mM.
- In a third embodiment the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody or an antigen-binding fragment thereof at a concentration of from 1 to 200 mg/ml, preferably from 90 to 180 mg/ml. In a fourth embodiment the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody or an antigen-binding fragment thereof which specifically binds to human sclerostin and/or is a human or humanized antibody.
- In a fifth embodiment the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises:
-
- 1. an antibody or antigen-binding fragment thereof which
- a. comprises CDR-H1 having the sequence as defined in SEQ ID NO:1; CDR-H2 having the sequence as defined in SEQ ID NO:2; CDR-H3 having the sequence as defined in SEQ ID NO:3; CDR-L1 having the sequence as defined in SEQ ID NO:4; CDR-L2 having the sequence as defined in SEQ ID NO:5 and CDR-L3 having the sequence as defined in SEQ ID NO:6; or
- b. has a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy variable region having the sequence as defined in SEQ ID NO: 8; or
- 2. an antibody which has
- a. a light chain having the sequence as defined in SEQ ID NO: 9 and a heavy chain having the sequence as defined in SEQ ID NO: 10; or
- b. a light chain having the sequence as defined in SEQ ID NO: 11 and a heavy chain having the sequence as defined in SEQ ID NO: 12.
- 1. an antibody or antigen-binding fragment thereof which
- In a sixth embodiment the liquid pharmaceutical formulation according to the first aspect and its embodiments comprises an antibody which is romosozumab.
- In a seventh embodiment, liquid formulation according to the first aspect and its embodiments has pH of from 4.0 to 7.5.
- In an eight embodiment the liquid formulation according to the first aspect and its embodiments comprises a cyclodextrin selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin), cyclodextrin-containing polymers or combinations thereof. Preferably, the cyclodextrin is selected from hydroxypropyl-gamma-cyclodextrin.
- In an ninth embodiment the liquid formulation according to the first aspect and its embodiments comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006
% polysorbate 20, from 55 mM to 80 mM hydroxypropyl-gamma-cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; preferably form 90 mg/ml to 180 mg/ml, more preferably from 120 mg/ml to 180 mg/ml of romosozumab. - In a second aspect the present invention provides for the liquid formulation according to the first aspect and its embodiments for use in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength. Alternatively, the present invention provides for the use of the liquid formulation according to the first aspect and its embodiments in the manufacture of a medicament for the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- Furthermore, in a third aspect the present invention provides for a method for treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength in a mammalian subject comprising administering a therapeutically effective amount of the formulation according to the first aspect and its embodiments.
- Preferably, in embodiments of the second and third aspects of the invention, the bone disorder is osteoporosis.
- In a fourth aspect the invention provides for a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation, the method comprising providing a liquid formulation and adding to the formulation methionine and cyclodextrin, preferably hydroxylpropyl-gamma-cyclodextrin.
- Finally, in a fifth aspect, the present invention provides for a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of the formulation according to the first aspect and its embodiments.
-
FIG. 1 shows the sequence of the light chain of romosozumab (SEQ ID NO: 11). The amino acid sequence is presented using three-letter symbols with the corresponding one-letter symbol beneath each amino acid. Intrachain disulfide bonds are indicated by lines between linked cysteines. Cysteines forming interchain bonds are indicated in boxes. -
FIG. 2 shows the sequence of the heavy chain of romosozumab (SEQ ID NO: 12). The amino acid sequence is presented using three-letter symbols with the corresponding one-letter symbol beneath each amino acid. Intrachain disulfide bonds are indicated by lines between linked cysteines. Cysteines forming interchain bonds are indicated in boxes. - The liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of two stabilizers, methionine and cyclodextrin.
- The synergistic combination of methionine and cyclodextrin provides the additional advantages of reducing the rate of precipitation of the antibody or the antigen-binding fragment thereof in the form of aggregates over time thus potentially reducing the occurrence of injection side reactions. Therefore, the present invention also provides for a method for reducing precipitation of an antibody or antigen-binding fragment thereof in a liquid pharmaceutical formulation, the method comprising providing a liquid formulation and adding to the formulation methionine and cyclodextrin.
- The concentration of cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 25 0mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- The concentration of methionine in the liquid pharmaceutical formulation may be from 7.5 mM to 200 mM or from 15 mM to 200 mM or from 30 mM to 200 mM or from 55 mM to 160 mM or preferably from 55 mM to 125 mM.
- In one embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of cyclodextrin to methionine.
- In one preferred embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of cyclodextrin.
- In particular, the cyclodextrin may be selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin), cyclodextrin-containing polymers or combinations thereof.
- The most common natural cyclodextrins are alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin, all of which are hydrophilic. Substitutions of the hydroxyl groups further enhance the cyclodextrin solubility (Loftsson T. et al, Expert Opin. Drug Deliv. 2, 335-351 (2005); Davis M.E. & Brewster M.E., Nature Reviews —
Drug discovery 3, 1023-1035 (2004)). - Chemically modified (i.e. substituted at the hydroxyl groups) cyclodextrins of interest are mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin) or combination thereof.
- Hence, the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of methionine and a chemically modified cyclodextrin, preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin) or combination thereof.
- The concentration of the chemically modified cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 250 mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- In one embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of chemically modified cyclodextrin to methionine.
- In one preferred embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of a chemically modified cyclodextrin.
- The preferred cyclodextrin according to the present invention is hydroxypropyl-gamma-cyclodextrin such as 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin, 2,3-dihydroxypropyl-gamma-cyclodextrin or combinations thereof.
- Hence, in one preferred embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, and the combination of methionine and hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin, 2,3-dihydroxypropyl-beta-cyclodextrin or combinations thereof).
- The concentration of hydroxypropyl-gamma-cyclodextrin in the liquid pharmaceutical formulation may be from 7.5 mM to 250 mM, or from 16 mM to 250 mM, or from 32 mM to 200 mM, or from 63 mM to 160 mM or preferably from 55 mM to 80 mM.
- In another embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or antigen binding fragment thereof as active ingredient and a ratio of from 1:1 to 1:3, preferably a ratio of 1:2 of hydroxypropyl-gamma-cyclodextrin to methionine.
- In another embodiment, the liquid pharmaceutical formulation according to the invention comprises an antibody or an antigen-binding fragment thereof as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of hydroxypropyl-gamma-cyclodextrin.
- The concentration of antibody or antigen-binding fragment thereof in the liquid formulation according to the present invention may be from 1 to 200 mg/ml, or from to 200 mg/ml, or from to 200mg/ml or preferably from 90 to 180 mg/ml. In another embodiment, the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of cyclodextrin.
- In particular, the cyclodextrin may be selected from beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin), cyclodextrin-containing polymers or combinations thereof.
- In another embodiment, the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of a chemically modified cyclodextrin, preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin) or combinations thereof.
- In one preferred embodiment, the liquid pharmaceutical formulation according to the invention comprises from 90 mg/ml to 180 mg/ml of an antibody as active ingredient, from 55 mM to 160 mM of methionine and from 55 mM to 100 mM of hydroxypropyl-gamma-cyclodextrin such as 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin, 2,3-dihydroxypropyl-gamma-cyclodextrin or combinations thereof.
- The active ingredient comprised in the liquid pharmaceutical formulation according to the invention is preferably an antibody. Preferably the antibody has an isoelectric point (pl) lower than the physiological pH (−7.0) but higher than the formulation pH. In one embodiment the liquid formulation according to the present invention and its embodiments comprises from 1 to 200 mg/ml of an antibody, wherein the antibody has a pl of from 5.0 to 6.9, preferably from 5.3 to 6.9.
- Preferably the antibody comprised in the liquid pharmaceutical formulation according to the invention specifically binds to human sclerostin.
- The term “specifically binds to human sclerostin”, “specifically binding to human sclerostin”, and equivalents as used herein when referring to an antibody means the antibody will bind to human sclerostin with sufficient affinity and specificity to achieve a biologically meaningful effect. The antibody selected will normally have a binding affinity for human sclerostin, for example, the antibody may bind human sclerostin with a Kd value of between 100 nM and 1 pM. Antibody affinities may be determined by a surface plasmon resonance bases assay, such as the BlAcore assay; enzyme-linked immunoabsorbent assay (ELISA); and competition assays (e.g. RIA's), for example. Within the meaning of the present invention an antibody specifically binding to human sclerostin may also bind to another molecule, e.g. mouse sclerostin or such as by way of a non-limiting example in the case of a bispecific antibody.
- Sclerostin, a protein encoded by the SOST gene, is a glycoprotein secreted by osteocytes and is a potent inhibitor of osteoblastogenesis. Loss-of-function mutations in SOST are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of the SOST gene, which results in reduced sclerostin expression, is associated with a milder form of the disease called van Buchem disease. Furthermore, SOST-null mice have a high-bone-mass phenotype.
- The antibody or antigen-binding fragment thereof binding specifically to human sclerostin, preferably also neutralizes human sclerostin.
- The term “neutralizes” as used herein refers to an antibody that inhibits or substantially reduces the biological effect of the molecule to which it specifically binds. Therefore, the expression “the antibody neutralizes human sclerostin” refers to an antibody that specifically binds to human sclerostin and inhibits or substantially reduces the biological effect thereof.
- The term “antibody” or “antibodies” as used herein refers to monoclonal or polyclonal antibodies. The term “antibody” or “antibodies” as used herein includes but is not limited to recombinant antibodies that are generated by recombinant technologies as known in the art.
- Preferably, the antibody comprised in the liquid formulation according to the invention is a monoclonal antibody which specifically binds human sclerostin.
- “Antibody” or “antibodies” include antibodies' of any species, in particular of mammalian species, having two essentially complete heavy and two essentially complete light chains, human antibodies of any isotype, including IgA1, IgA2, IgD, IgG1, IgG2a, IgG2b, IgG3, IgG4 IgE and IgM and modified variants thereof, non-human primate antibodies, e.g. from chimpanzee, baboon, rhesus or cynomolgus monkey, rodent antibodies, e.g. from mouse, rat or rabbit; goat or horse antibodies, and camelid antibodies (e.g. from camels or llamas such as Nanobodies™) and derivatives thereof, or of bird species such as chicken antibodies or of fish species such as shark antibodies. The term “antibody” or “antibodies” also refers to “chimeric” antibodies in which a first portion of at least one heavy and/or light chain antibody sequence is from a first species and a second portion of the heavy and/or light chain antibody sequence is from a second species. Chimeric antibodies of interest herein include “primatized” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, such as baboon, rhesus or cynomolgus monkey) and human constant region sequences. “Humanized” antibodies are chimeric antibodies that contain a sequence derived from non-human antibodies. For the most part, humanized antibodies are human antibodies (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region [or complementarity determining region (CDR)] of a non-human species (donor antibody) such as mouse, rat, rabbit, chicken or non-human primate, having the desired specificity, affinity, and activity. In most instances residues of the human (recipient) antibody outside of the CDR; i.e. in the framework region (FR), are additionally replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. Humanization reduces the immunogenicity of non-human antibodies in humans, thus facilitating the application of antibodies to the treatment of human diseases. Humanized antibodies and several different technologies to generate them are well known in the art. The term “antibody” or “antibodies” also refers to human antibodies, which can be generated as an alternative to humanization. For example, it is possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of production of endogenous murine antibodies. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies with specificity against a particular antigen upon immunization of the transgenic animal carrying the human germ-line immunoglobulin genes with said antigen. Technologies for producing such transgenic animals and technologies for isolating and producing the human antibodies from such transgenic animals are known in the art. Alternatively, in the transgenic animal; e.g. mouse, only the immunoglobulin genes coding for the variable regions of the mouse antibody are replaced with corresponding human variable immunoglobulin gene sequences. The mouse germline immunoglobulin genes coding for the antibody constant regions remain unchanged. In this way, the antibody effector functions in the immune system of the transgenic mouse and consequently the B cell development are essentially unchanged, which may lead to an improved antibody response upon antigenic challenge in vivo. Once the genes coding for a particular antibody of interest have been isolated from such transgenic animals the genes coding for the constant regions can be replaced with human constant region genes in order to obtain a fully human antibody. The term “antibody” or “antibodies” as used herein, also refers to an aglycosylated antibody.
- The term “antigen-binding fragment thereof” or grammatical variations thereof as used herein refers to an antibody fragment. A fragment of an antibody comprises at least one heavy or light chain immunoglobulin domain as known in the art and binds to one or more antigen(s). Examples of antibody fragments according to the invention include Fab, Fab′, F(ab′)2, and Fv and scFv fragments; as well as diabodies, triabodies, tetrabodies, minibodies, domain antibodies(dAbs), such as sdAbs, VHH and VNAR fragments, single-chain antibodies, bispecific, trispecific, tetraspecific or multispecific antibodies formed from antibody fragments or antibodies, including but not limited to Fab-Fv or Fab-Fv-Fv constructs. Antibody fragments as defined above are known in the art.
- The antibody or antigen-binding fragment thereof comprised as active ingredient in the liquid pharmaceutical formulation according to the invention may be human or humanized antibody, preferably a humanized monoclonal antibody which specifically binds human sclerostin.
-
- 1) More preferably the liquid pharmaceutical formulation according to the invention comprises: an antibody or antigen-binding fragment thereof which
- a. comprises CDR-H1 having the sequence as defined in SEQ ID NO:1; CDR-H2 having the sequence as defined in SEQ ID NO:2; CDR-H3 having the sequence as defined in SEQ ID NO:3; CDR-L1 having the sequence as defined in SEQ ID NO:4; CDR-L2 having the sequence as defined in SEQ ID NO:5 and CDR-L3 having the sequence as defined in SEQ ID NO:6; or
- b. has a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy variable region having the sequence as defined in SEQ ID NO: 8; or
- 2) an antibody which has
- a. a light chain having the sequence as defined in SEQ ID NO: 9 and a heavy chain having the sequence as defined in SEQ ID NO: 10; or
- b. a light chain having the sequence as defined in SEQ ID NO: 11 and a heavy chain having the sequence as defined in SEQ ID NO: 12.
- 1) More preferably the liquid pharmaceutical formulation according to the invention comprises: an antibody or antigen-binding fragment thereof which
- Throughout this specification, complementarity determining regions (“CDR”) are defined according to the Kabat definition. The Kabat definition is a standard for numbering the residues in an antibody and it is typically used to identify CDR regions (Kabat et al., (1991), 5th edition, NIH publication No. 91-3242).
- The sequences are shown in Table 1 below and in
FIGS. 1 and 2 . -
TABLE 1 Region and SEQ ID identifier Amino acid sequence CDR-H1 DYNMH SEQ ID NO: 1 CDR-H2 EINPNSGGAGYNQKFKG SEQ ID NO: 2 CDR-H3 LGYDDIYDDWYFDV SEQ ID NO: 3 CDR-L1 RASQDISNYLN SEQ ID NO: 4 CDR-L2 YTSRLLS SEQ ID NO: 5 CDR-L3 QQGDTLPYT SEQ ID NO: 6 Light variable DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSG region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK SEQ ID NO: 7 Heavy variable EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPN region SGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWY SEQ ID NO: 8 FDVWGQGTTVTVSS Light chain DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTS SEQ ID NO: 9 RLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy chain EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPN SEQ ID NO: 10 SGGAGYNQKPKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWY FDVWGQGTTVTYSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQ FNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK - Even more preferably, the antibody comprised as active ingredient in the liquid pharmaceutical formulation according to the invention is romosozumab, an anti-human sclerostin antibody as described in WO2006119107 and WO2011143307 (incorporated herein by reference).
- In particular, the present invention also provides for a liquid pharmaceutical formulation comprising romosozumab and a cyclodextrin, preferably selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin), cyclodextrin-containing polymers or combinations thereof, more preferably the liquid pharmaceutical formulation comprising romosozumab and hydroxypropyl-gamma-cyclodextrin.
- The liquid pharmaceutical formulation according to any of the embodiments of the invention may contain a buffering agent to maintain a constant pH during storage and administration. There are many buffering agents used in the field of liquid pharmaceutical formulations, such as, but not limited to, citrate, phosphate, lactate, histidine, glutamate, maleate, tartrate, or succinate. A preferred buffer species is typically selected amongst those having a pKa that is close (±1 pH unit) to the preferred pH for optimal protein stability in order to maintain high buffering capacity, and is associated with the maximal demonstrated stability observed for a particular protein when placed in a series of varied buffer species. The adequate pH ranges of a formulation are generally chosen from those associated with the maximal demonstrated stability observed for a particular protein when placed in a series of varied pH formulations.
- In a particular embodiment of the invention, the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises sodium acetate, preferably at a concentration of 10 mM to 100 mM, 10 mM to 80 mM, 10 mM to 60 mM, 25 mM to 60 mM, preferably 40 mM to 60 mM, or 50 mM. The liquid pharmaceutical formulation according to the invention may also comprise calcium acetate, preferably at a concentration of 0.5 mM to 50 mM, 5 mM to 40 mM, 10 mM to 30 mM or 14 mM. More preferably, the liquid pharmaceutical formulation according to the invention comprises 50 mM sodium acetate and 14 mM calcium acetate.
- In a further embodiment, the liquid pharmaceutical formulation according to any of the embodiments of the invention may have a pH of 4 to 7.5, preferably 4 to 6, preferably 4.5 to 5.5, or 5.2.
- In a further embodiment the liquid pharmaceutical formulation according to any of the embodiments of the invention additionally comprises a surfactant. The skilled artisan is aware of the choice of surfactants available for use in the liquid formulation according to any of the embodiments of the invention such as but not limited to polysorbate 80,
polysorbate 20, lecithin, poloxamer (e.g. poloxamer 188), sodium dodecyl sulfate (SDS), sodium laurel sulfate, sodium octyl glycoside, lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine, lauryl-, myristyl-, linoleyl- or stearyl-sarcosine, linoleyl-, myristyl-, or cetyl-betaine, lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine, sodium methyl cocoyl-, or disodium methyl oleyl-taurate, polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol. In a further embodiment of the invention, the liquid pharmaceutical formulation may comprisepolysorbate 20. - The liquid formulation of the invention may comprise from 0.001% to 10
% Polysorbate 20, from 0.001% to 5% Polysorbate 20, from 0.001 to 1% Polysorbate 20, from 0.001 to 0.006% Polysorbate 20, or 0.006% Polysorbate 20. - The liquid formulation according to the embodiments of the invention may further comprise additional excipients commonly used in the preparation of liquid pharmaceutical formulations including but not limited to sugars (e.g. sucrose or treahalose), poly-ethylene glycols (e.g. PEG100, PEG300, PEG600, PEG1500, PEG2000, PEG3000, PEG3350, PEG4000, PEG6000, PEG8000 or PEG20000), polyols (e.g. mannitol, sorbitol or lactitol), other amino acids than methionine, polyvinylpyrrolidone, trimethylamine N-oxide, trimethylglycine or combinations thereof.
- In particular, the liquid formulation according to the embodiments of the invention may further comprise sucrose, from 0 to 6% sucrose, more preferably 6% sucrose.
- In an another embodiment the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006
% polysorbate 20, from 55 mM to 80 mM of a chemically modified cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; more preferably form 90 mg/ml to 180 mg/ml and even more preferably from 120 mg/ml to 180 mg/ml of antibody, wherein the chemically modified cyclodextrin is preferably selected from mono, di or trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin) or combinations thereof. - In a further embodiment the liquid pharmaceutical formulation according to any of the embodiments of the invention comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006
% polysorbate 20, from 55 mM to 80 mM hydroxypropyl-gamma-cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2; more preferably form 90 mg/ml to 180 mg/ml and even more preferably from 120 mg/ml to 180 mg/ml of antibody. - In a preferred embodiment, the liquid pharmaceutical formulation according to the invention comprises at least 90 mg/ml antibody, 55 mM hydroxypropyl-gamma-cyclodextrin, 125 mM methionine 55 mM sodium acetate buffer at
pH 5, 14 mM calcium acetate, 6% sucrose and 0.006% polysorbate 20, wherein the antibody is an anti-human sclerostin antibody. Even more preferably the liquid pharmaceutical formulation according to the invention comprises at least 90 mg/ml antibody, 55 mM hydroxypropyl-gamma-cyclodextrin, 125 mM methionine 55 mM sodium acetate buffer atpH 5, 14 mM calcium acetate, 6% sucrose and 0.006% polysorbate 20, wherein the antibody is an anti-human sclerostin antibody and the formulation is for subcutaneous administration. - In another embodiment the liquid pharmaceutical formulation according to any of the embodiments of the invention exhibits an osmolality of 800 mOsm/l or less and/or a viscosity of 80 cP or less.
- In an embodiment the liquid formulation is not a hydrogel. In an embodiment the liquid formulation comprises at least 2%, at least 5%, at least 10%, at least 25%, between 2% and 90%, between 2% and 75%, or between 2% and 50% water.
- The liquid pharmaceutical formulation according to any of the embodiments of the invention may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength. In addition, the invention provides for a method of treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strengthin a mammalian subject comprising administering a therapeutically effective amount of the liquid pharmaceutical formulation according to any of the embodiments of the invention. Furthermore, the invention provides for the use of the liquid formulation according to any one of the embodiments of the invention for the manufacture of a medicament for the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
- The mammalian subject may be selected from the group of rodents, cats, dogs, horses, bovine, ovine, non-human primates and human subjects. Preferably, the mammalian subject is a human subject.
- The invention is typically used to treat or help prevent a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength. The bone disorder is characterized by an altered function of sclerostin or by an increased/decreased expression of sclerostin protein in relevant tissue (e.g. bone, cartilage). The invention may be, for example, employed to increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength.
- The bone disorder may be associated with abnormal osteoblast or osteoclast activity, with decreased bone density, increased bone resorption and/or bone-related disorders, i.e. osteoporosis. In particular, the bone disorder may be selected from the group of achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's Disease, hypophosphatemia rickets, Marfan's syndrome, multiple hereditary exotoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, pseudoarthrosis, pyogenic osteomyelitis, periodontal disease, anti-epileptic drug induced bone loss, primary and secondary hyperparathyroidism, familial hyperparathyroidism syndromes, weightlessness induced bone loss, osteoporosis in men, postmenopausal bone loss, osteoarthritis, renal osteodystrophy, infiltrative disorders of bone, oral bone loss, osteonecrosis of the jaw, juvenile Paget's disease, melorheostosis, metabolic bone diseases, mastocytosis, sickle cell anemia/disease, organ transplant related bone loss, kidney transplant related bone loss, systemic lupus erythematosus, ankylosing spondylitis, epilepsy, juvenile arthritides, thalassemia, mucopolysaccharidoses, Fabry Disease, Turner Syndrome, Down Syndrome,
- Klinefelter Syndrome, leprosy, Perthes' Disease, adolescent idiopathic scoliosis, infantile onset multi-system inflammatory disease, Winchester Syndrome, Menkes Disease, Wilson's Disease, ischemic bone disease (such as Legg-Calve-Perthes disease, regional migratory osteoporosis), anemic states, conditions caused by steroids, glucocorticoid-induced bone loss, heparin-induced bone loss, bone marrow disorders, scurvy, malnutrition, calcium deficiency, osteoporosis, osteopenia, alcoholism, chronic liver disease, postmenopausal state, chronic inflammatory conditions, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, inflammatory colitis, Crohn's disease, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, thyroid disorders, parathyroid disorders, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, regional osteoporosis, osteomalacia, bone gap defect, alveolar bone loss, bone loss associated with joint replacement, HIV associated bone loss, bone loss associated with loss of growth hormone, bone loss associated with cystic fibrosis, chemotherapy associated bone loss, tumor induced bone loss, cancer-related bone loss, hormone ablative bone loss, multiple myeloma, drug-induced bone loss, anorexia nervosa, disease associated facial bone loss, disease associated cranial bone loss, disease associated bone loss of the jaw, disease associated bone loss of the skull, bone loss associated with aging, facial bone loss associated with aging, cranial bone loss associated with aging, jaw bone loss associated with aging, skull bone loss associated with aging and bone loss associated with space travel and combinations thereof.
- Bone loss, decreased bone mineral density, decreased bone volume, and/or decreased bone mineral content associated with these disorders may be treated in the context of the invention. In one instance, the subject to be treated may be pregnant. For instance, the invention may be employed to help in pregnancy-related bone loss. The invention may be used to slow, or reverse, bone loss in general.
- In one preferred embodiment, the bone disorder to be treated is osteoporosis or osteopenia. In one instance, the mammalian subject to be treated is a postmenopausal woman, for instance, one with osteoporosis, particularly such a subject who is at increased, or high risk, for fracture, or has failed or is intolerant to other available osteoporosis therapy. In further instances, the invention may be employed in improving the outcome in a mammal undergoing one or more of an orthopedic procedure, dental procedure, implant surgery, joint replacement, bone grafting, bone cosmetic surgery and bone repair such as fracture healing, nonunion healing, delayed union healing and facial reconstruction.
- In another preferred embodiment, the subject has, or is thought at risk of, a bone fracture. For instance, it may be that the subject has a bone mineral density that identifies them at risk of bone fracture. It may be that the subject has recently been diagnosed with a bone disorder as a result of a bone fracture. In some instances, it may be that the subject has a fracture of the wrist, arm, leg, hip or vertebrae and in some cases it may be that the fracture has resulted in the diagnosis of the bone disorder.
- Preferably, the bone disorder is selected from osteoporosis, bone gap defect, alveolar bone loss, inhibited bone resorption or combinations thereof.
- The present invention also provides for a method for reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of the liquid pharmaceutical formulation according to any of the embodiments of the invention.
- The liquid pharmaceutical formulations according to the invention are administered in a therapeutically effective amount. The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent (i.e. active ingredient) needed to treat, ameliorate or prevent a targeted disease, disorder or condition, or to exhibit a detectable therapeutic, pharmacological or preventative effect. For any antibody or antigen-binding fragments thereof, the therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- The precise therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, a therapeutically effective amount of antibody will be from 0.01 mg/kg to 500 mg/kg, for example 0.1 mg/kg to 200 mg/kg, such as 100 mg/kg.
- The liquid pharmaceutical formulation may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose.
- For the treatment of the above diseases and/or disorders, the appropriate dosage will vary depending upon, for example, the particular antibody to be employed, the subject treated, the mode of administration and the nature and severity of the condition being treated. In a particular embodiment the liquid pharmaceutical formulation of the invention is administered by intravenous or subcutaneous route. When administered via intravenous injection, it may be administered as a bolus injection or as a continuous infusion. The liquid pharmaceutical formulation according to any of the embodiments of the invention may also be administered by intramuscular injection. The liquid pharmaceutical formulation may be injected using a syringe, an injection device such as an autoinjector, a needleless device, an implant and a patch. The liquid pharmaceutical formulation of the invention may also be administered via inhalation using an inhalation device containing said formulation for such delivery, for example using a nebulizer or liquid inhaler.
- The liquid pharmaceutical formulation of the invention is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards; it may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the conditions as described herein before.
- The antibody or antigen-binding fragment thereof may be the sole active ingredient in the liquid pharmaceutical formulation. Alternatively, the antibody or antigen-binding fragment thereof may be administered in combination, e.g. simultaneously, sequentially or separately, with one or more other therapeutically active ingredients. Active ingredient as employed herein refers to an ingredient with a pharmacological effect, such as a therapeutic effect, at a relevant dose. In some embodiments the antibody or antigen-binding fragment thereof in the liquid pharmaceutical formulation may be accompanied by other active ingredients including other antibodies or non-antibody ingredients. When the antibody in the liquid pharmaceutical formulation according to the invention is an anti-sclerostin antibody, the subject may be administered with an additional active ingredient to treat their bone disorder. The subject may be, for instance, treated with any other therapy for treating bone disorders. In one embodiment, the subject is administered an anti-resorptive, in a particularly preferred instance the additional agent is administered at a time when the subject is not being treated with the liquid pharmaceutical formulation according to the invention and its embodiments. In an alternative embodiment, such an additional active ingredient may be administered at the same time or overlapping with the administration of the liquid pharmaceutical formulation according to the invention. In any embodiment discussed herein, the additional agent may be, for instance, vitamin D. In some embodiments, the other therapeutic active ingredient may be a bone resorption inhibitor. For instance, any suitable anti-resorptive may be employed. In one preferred embodiment, the bone resorption inhibitor is a bisphosphonate, particularly a nitrogen containing bisphosphonate. Examples of bisphosphonates include, but are not limited to, Alendronate, bonefos ciodronate, etidronate, ibandronic acid, olpadronate, neridronate, risedronate sodium, skelid, and zoledronic acid. In another preferred embodiment, the bisphosphonate is zoledronic acid. Bisphosphonates which may be employed include, for instance, Actonel™, Aclasta™/Reclast™, Boniva™/Bonviva™, Fosamax™, and Zometa™. An advantage of alternating between the liquid pharmaceutical formulation comprising an anti-sclerostin antibody and bisphosphonate is that it may help avoid possible side effects arising from the subject being treated with bisphosphonates for a prolonged period. Hence, alternating helps avoid such side-effects, whilst also addressing the problem of resistance developing to the antibody. In a preferred embodiment, the additional active ingredient is an anti-resorptive and even more preferably is Alendronate.
- Selected estrogen receptor modulators may also be employed as bone resorption inhibitors, for instance, arzoxifene, bazedoxifene, FC 1271, lasofoxifene, raloxifene, and Tibolone are examples of suitable SERMs. Other bone resorption inhibitors which may be used include estrogen and calcitonin, with examples of calcitonin including salmon calcitonins, such as Miacalcin™.
- Strontium compounds, in particular strontium ranelate, or PTH, in particular recombinant parathyroid hormone releasing peptide, parathyroid hormone or analogs thereof (e.g., teriparatide (FORTEO®), may also be employed as the bone resorption inhibitor.
- In other embodiments, the bone resorption inhibitor is a RANKL inhibitor, such as an anti-RANKL antibody. In one preferred embodiment, the bone resorption inhibitor employed may be denosumab.
- In other embodiments the anti-resorptive employed is not a bisphosphonate. Examples, of such agents which may be employed include PROLIA®, calcitonin, and cathepsin K inhibitors (e.g., odanacatib).
- In one case, a bone resorption inhibitor may be administered at the same time, or approximately the same time, as the antibody, or so the two therapies overlap. It may be that the bone resorption inhibitor is given to help prolong further the effect of the anti-sclerostin antibody by reducing the breakdown of bone that the antibody has stimulated and in particular where the compound is a bisphosphonate. In one preferred instance, there is no overlap in the treatment of the subject with anti-sclerostin antibody and the further treatment for the bone disorder, for instance the two treatments are alternated, but never overlap.
- Antibody molecules may be typically produced by culturing a host cell containing a vector encoding the antibody sequence under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.
- The antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host cells. For production of products comprising both heavy and light chains, the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.
- An antibody or an antigen-binding fragment thereof that can be manufactured according to industrial scales can be produced by culturing eukaryotic host cells transfected with one or more expression vectors encoding the recombinant antibody fragment. The eukaryotic host cells are preferably mammalian cells, more preferably Chinese Hamster Ovary (CHO) cells.
- Mammalian cells may be cultured in any medium that will support their growth and expression of the recombinant protein, preferably the medium is a chemically defined medium that is free of animal-derived products such as animal serum and peptone. There are different cell culture mediums available to the person skilled in the art comprising different combinations of vitamins, amino acids, hormones, growth factors, ions, buffers, nucleosides, glucose or an equivalent energy source, present at appropriate concentrations to enable cell growth and protein production. Additional cell culture media components may be included in the cell culture medium at appropriate concentrations at different times during a cell culture cycle that would be known to those skilled in the art.
- Mammalian cell culture can take place in any suitable container such as a shake flask or a bioreactor, which may or may not be operated in a fed-batch mode depending on the scale of production required. These bioreactors may be either stirred-tank or air-lift reactors. Various large scale bioreactors are available with a capacity of more than 1,000 L to 50,000 L, preferably between 5,000 L and 20,000 L, or to 10,000 L. Alternatively, bioreactors of a smaller scale such as between 2 L and 100 L may also be used to manufacture an antibody or antibody fragment.
- An antibody or antigen-binding fragment thereof is typically found in the supernatant of a mammalian host cell culture, typically a CHO cell culture. For CHO culture processes wherein the protein of interest such as an antibody or antigen-binding fragment thereof is secreted in the supernatant, said supernatant is collected by methods known in the art, typically by centrifugation.
- Therefore, the antibody or antigen-binding fragment thereof production method comprises a step of centrifugation and supernatant recovery after cell culture and prior to protein purification. In a further particular embodiment said centrifugation is continuous centrifugation. For avoidance of doubt, supernatant denotes the liquid lying above the sedimented cells resulting from the centrifugation of the cell culture.
- Alternatively, host cells are prokaryotic cells, preferably gram-negative bacteria. More preferably, the host cells are E. coli cells. Prokaryotic host cells for protein expression are well known in the art (Terpe, K. Appl Microbiol Biotechnol 72, 211-222 (2006)). The host cells are recombinant cells which have been genetically engineered to produce the protein of interest such as an antigen-binding fragment of an antibody. The recombinant E. coli host cells may be derived from any suitable E. coli strain including from MC4100, TG1, TG2, DHB4, DH5a, DH1, BL21, K12, XL1Blue and JM109. One example is E. coli strain W3110 (ATCC 27,325) a commonly used host strain for recombinant protein fermentations. Antibody fragments can also be produced by culturing modified E. coli strains, for example metabolic mutants or protease deficient E. coli strains.
- An antibody fragment is typically found in either the periplasm of the E. coli host cell or in the host cell culture supernatant, depending on the nature of the protein, the scale of production and the E. coli strain used. The methods for targeting proteins to these compartments are well known in the art (Makrides, S. C.;
Microbiol Rev 60, 512-538 (1996)). Examples of suitable signal sequences to direct proteins to the periplasm of E. coli include the E. coli PhoA, OmpA, OmpT, LamB and OmpF signal sequences. Proteins may be targeted to the supernatant by relying on the natural secretory pathways or by the induction of limited leakage of the outer membrane to cause protein secretion examples of which are the use of the pelB leader, the protein A leader, the co-expression of bacteriocin release protein, the mitomycin-induced bacteriocin release protein along with the addition of glycine to the culture medium and the co-expression of the kil gene for membrane permeabilization. Most preferably, the recombinant protein is expressed in the periplasm of the host E. coll. - Expression of the recombinant protein in the E. coli host cells may also be under the control of an inducible system, whereby the expression of the recombinant antibody in E. coli is under the control of an inducible promoter. Many inducible promoters suitable for use in E. coli are well known in the art and depending on the promoter expression of the recombinant protein can be induced by varying factors such as temperature or the concentration of a particular substance in the growth medium. Examples of inducible promoters include the E.coli lac, tac, and trc promoters which are inducible with lactose or the non-hydrolyzable lactose analog, isopropyl-b-D-1-thiogalactopyranoside (IPTG) and the phoA, trp and araBAD promoters which are induced by phosphate, tryptophan and L-arabinose respectively. Expression may be induced by, for example, the addition of an inducer or a change in temperature where induction is temperature dependent. Where induction of recombinant protein expression is achieved by the addition of an inducer to the culture the inducer may be added by any suitable method depending on the fermentation system and the inducer, for example, by single or multiple shot additions or by a gradual addition of inducer through a feed. It will be appreciated that there may be a delay between the addition of the inducer and the actual induction of protein expression for example where the inducer is lactose there may be a delay before induction of protein expression occurs while any pre-existing carbon source is utilized before lactose.
- E. coli host cell cultures (fermentations) may be cultured in any medium that will support the growth of E. coli and expression of the recombinant protein. The medium may be any chemically defined medium such as e.g. described in Durany O, et al. (2004). Studies on the expression of recombinant fuculose-1-phosphate aldolase in Escherichia coli.
Process Biochem 39, 1677-1684. - Culturing of the E. coli host cells can take place in any suitable container such as a shake flask or a fermenter depending on the scale of production required. Various large scale fermenters are available with a capacity of more than 1,000 liters up to about 100,000 liters. Preferably, fermenters of 1,000 to 50,000 liters are used, more preferably 1,000 to 25,000, 20,000, 15,000, 12,000 or 10,000 liters. Smaller scale fermenters may also be used with a capacity of between 0.5 and 1,000 liters.
- Fermentation of E. coli may be performed in any suitable system, for example continuous, batch or fed-batch mode depending on the protein and the yields required. Batch mode may be used with shot additions of nutrients or inducers where required. Alternatively, a fed-batch culture may be used and the cultures grown in batch mode pre-induction at the maximum specific growth rate that can be sustained using the nutrients initially present in the fermenter and one or more nutrient feed regimes used to control the growth rate until fermentation is complete. Fed-batch mode may also be used pre-induction to control the metabolism of the E. coli host cells and to allow higher cell densities to be reached.
- If desired, the host cells may be subject to collection from the fermentation medium, e.g. host cells may be collected from the sample by centrifugation, filtration or by concentration. In this case the process typically comprises a step of centrifugation and cell recovery prior to extracting the protein.
- For E. coli fermentation processes wherein the protein of interest such as an antibody or antigen-binding fragment of an antibody is found in the periplasmic space of the host cell it is required to release the protein from the host cell. The release may be achieved by any suitable method such as cell lysis by mechanical or pressure treatment, freeze-thaw treatment, osmotic shock, extraction agents or heat treatment. Such extraction methods for protein release are well known in the art. Therefore in a particular embodiment, the production process comprises an additional protein extraction step prior to protein purification.
- Other methods for obtaining antigen-binding fragment of a human antibody in vitro are based on display technologies such as phage display or ribosome display technology, wherein recombinant DNA libraries are used that are either generated at least in part artificially or from immunoglobulin variable (V) domain gene repertoires of donors. Phage and ribosome display technologies for generating human antibodies are well known in the art. Human antibodies may also be generated from isolated human B cells that are ex vivo immunized with an antigen of interest and subsequently fused to generate hybridomas which can then be screened for the optimal human antibody.
- Stability and propensity to precipitate within a formulation is greatly affected by the concentration (steric crowding) and the excipients used within the formulation to control the interactions observed due to steric crowding.
- In order to determine whether HPGCD has an impact on the precipitation profile at physiological pH, basic formulation of romosozumab (pl 6.9) at a concentration of 120 mg/mL with and without HPGCD were run through the pH shift model.
- The pH shift model is designed to replicate the pH shift that occurs when a formulation comprising a drug is administered by subcutaneous injection (Elena Garcia-Fruitos, Insoluble Proteins: Methods and Protocols, Methods in Molecular Biology, vol. 1258, Chapter 18:321-330, Springer Science+Business Media New York (2015)). Biotherapeutic proteins, in particular antibodies, are often formulated below physiological pH (−pH7.0). If the pl of the protein is less than pH 7.0 but higher than the formulation pH, the protein will shift through its pl. This will reduce the solubility of the protein and cause it to precipitate. This model is designed to replicate this pH shift and aid in assessing formulations' suitability for subcutaneous injection.
- The model is run over 24 hours. A tissue buffer (10 mM Sodium Bicarbonate and 150 mM Sodium Chloride) is prepared the day before and placed into the CO2 incubator at 37° C./7% CO2 on a gentle stir overnight to equilibrate. About 0.5 mL of each test sample is loaded into a slide-a-lyser cassette according to the manufacturer 'instructions (Thermo Scientific, Slide-A-Lyzer Dialysis Cassettes G2, Prod#87727, 7000 MWCO, 0.5 mL). The slide-a-lyser cassettes are gently placed into the equilibrated tissue buffer within the CO2 incubator and left overnight. The slide-a-lyser cassettes are visually assessed against a white and black background for signs of precipitation every hour for the first 4-6 hours and then after 24 hours (or longer).
- Romosozumab at 120 mg/mL in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006
% polysorbate 20 at pH 5.2 (drug solution, DS) were prepared by performing a 1:1 serial dilution. An initial solution was prepared by adding 881 mg of HPGCD to 2 ml of romosozumab at 120 mg/mL in DS to give a final HPGCD concentration of 250 mM. Half of this solution (1 mL) was mixed 1:1 with the same volume of romosozumab at 120 mg/mL in DS to achieve a sample of romosozumab at 120 mg/mL in DS with 125 mM HPGCD. This process was repeated to achieve samples of romosozumab at 120 mg/mL in DS with 62.5 mM, 31.25 mM, 15.63 mM and 7.8 mM HPGCD. Romosozumab at 120 mg/mL in DS was used as the control. - The formulations comprising 0 to 250 mM concentrations of HPGCD were buffer exchanged and concentrated using 30 kDa Sartorius Viva Spin centrifugal spin filters of varying volumes (2-20 mL). The spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes. Samples were mixed between spin cycles using a positive displacement pipette volume exchange.
- The concentration of each sample was measured in duplicate before and after dialysis (Table 2) using the C Technologies Solo VPE high concentration UV spectrophotometer linked to a
Cary 50 spectrophotometer. Concentration was determined by absorbance at A280. Result reported as mean of duplicate sample readings. The pH was determined using the Hach H260G pH meter and ISFET solid state probe. All samples were stored at 5° C. after preparation. -
TABLE 2 Replicates Sample 1 2 Mean SD % CV Pre-dialysis 0 mM HPGCD 122.18 120.58 121.38 1.13 0.93 7.8 mM HPGCD 120.15 120.60 120.38 0.32 0.26 15.6 mM HPGCD 122.61 120.80 121.71 1.28 1.05 31.3 mM HPGCD 118.52 119.04 118.79 0.36 0.31 62.5 mM HPGCD 114.86 115.69 115.28 0.59 0.51 125 mM HPGCD 109.36 109.20 109.29 0.11 0.10 250 mM HPGCD 96.77 96.82 96.8 0.03 0.03 Post-dialysis 0 mM HPGCD 29.18 28.99 29.1 0.13 0.45 7.8 mM HPGCD 29.42 27.66 28.5 1.24 4.35 15.6 mM HPGCD 26.89 26.78 26.8 0.08 0.29 31.3 mM HPGCD 27.25 27.35 27.3 0.07 0.26 62.5 mM HPGCD 28.98 28.78 28.9 0.14 0.49 125 mM HPGCD — — — — — 250 mM HPGCD — — — — — - Visual assessment of the sample was performed each hour for the first five hours and after 72 hours. Results are reported in Table 3. Addition of HPGCD reduces the rate of precipitation.
-
TABLE 3 Precipitation Assessment Time 0 mM 7.8 mM 15.6 mM 31.3 mM 62.5 mM 125 mM 250 mM (hr) HPGCD HPGCD HPGCD HPGCD HPGCD HPGCD HPGCD 0 No No No No No No No 1 Light Light Light Light No No No 2 Moderate Moderate Moderate Moderate Light No No 3 Heavy Heavy Heavy Heavy Moderate No No 4 Heavy Heavy Heavy Heavy Moderate Light No 5 Heavy Heavy Heavy Heavy Heavy Light No 72 Heavy Heavy Heavy Heavy Heavy Moderate Light - Once the impact of HPGCD on the precipitation profile of the basic romosozumab formulation of example 1 was assessed, the effect of methionine was investigated.
- In order to determine whether methionine has an impact on the precipitation profile at physiological pH, basic formulations of romosozumab (pl 6.9) at a concentration of 90 mg/ml (control only) 120 mg/mL or 180 mg/ml with (55 mM and 200 mM) and without methionine were run through the pH shift model described in example 1.
- Romosozumab in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006
% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to 125 mg/mL or to 190 mg/mL using 30 kDa Sartorius Viva Spin centrifugal spin filters. The spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes; samples were mixed between spin cycles using a positive displacement pipette. - The required amount of methionine to produce 2.2 mL of sample with the required concentration (55 and 200 mM) was weighed (0.018 g and 0.0066 g, respectively) using an analytical balance. Methionine was dissolved in 2.2 mL of the appropriate protein solution (125 mg/mL or 190 mg/mL).
- The concentration of each sample was measured in duplicate before and after dialysis (Table 4) using the C Technologies Solo VPE high concentration UV spectrophotometer linked to a
Cary 50 spectrophotometer. Concentration was determined by absorbance at Å280. Result reported as mean of duplicate sample readings. -
TABLE 4 Replicates Sample 1 2 Mean SD % CV Pre-dialysis 120 mg/mL 122.39 124.35 123.38 1.39 1.12 55 mM Meth 120 mg/mL 121.81 124.43 123.13 1.85 1.51 200 mM Meth 180 mg/mL 188.84 187.96 188.40 0.62 0.33 55 mM Meth 180 mg/mL 186.70 186.69 186.70 0.01 0.00 200 mM Meth 90 mg/mL 90.93 91.32 91.13 0.27 0.30 Control 120 mg/mL 118.18 119.16 118.67 0.69 0.58 Control 180 mg/mL 182.90 183.31 183.11 0.29 0.16 Control Post-dialysis 120 mg/mL 24.64 24.57 24.61 0.05 0.22 55 mM Meth 120 mg/mL 24.38 24.41 24.40 0.01 0.08 200 mM Meth 180 mg/mL 31.39 31.58 31.49 0.13 0.42 55 mM Meth 180 mg/mL 30.75 30.57 30.66 0.12 0.40 200 mM Meth 90 mg/mL 22.51 22.60 22.56 0.06 0.28 Control 120 mg/mL 23.54 23.57 23.56 0.02 0.10 Control 120 mg/mL 31.47 31.30 31.39 0.12 0.39 Control - The pH of the formulations pre-dialysis and after 24 h, measured using the Hach H260G pH meter and ISFET solid state probe, confirmed the pH shift (Table 5).
-
TABLE 5 pH Viscosity Osmolality Sample t0 t24 (cP) (mOsmol) 120 mg/mL 55 mM Meth 5.14 7.80 5.21 392 120 mg/mL 200 mM Meth 5.28 7.81 5.55 573 180 mg/mL 55 mM Meth 5.23 7.75 34.36 508 180 mg/mL 200 mM Meth 5.23 7.73 29.56 712 90 mg/mL Control 5.27 7.86 2.55 321 120 mg/mL Control 5.22 7.80 4.76 320 180 mg/mL Control 5.28 7.77 27.21 398 Tissue buffer 6.99 - Visual assessment of the sample was performed each hour for the first four hours. Results are reported in Table 6.
-
TABLE 6 120 mg/mL 120 mg/mL 180 mg/mL 180 mg/mL Time 55 mM 200 mM 55 mM 200 mM 90 mg/mL 120 mg/mL 180 mg/mL (hr) Meth Meth Meth Meth Control Control Control 0 No No No No No No No 1 Light Light Heavy Heavy Very Light Light Moderate 2 Heavy Heavy Very Heavy Very Heavy Moderate Moderate Very Heavy 3 Heavy Heavy Very Heavy Very Heavy Heavy Heavy Very Heavy 4 Heavy Heavy Very Heavy Very Heavy Heavy Heavy Very Heavy - As can be observed by the results reported in Table 6, the addition of methionine alone did not alter the rate of precipitation.
- Once assessed the impact of HPGCD alone or methionine alone on the precipitation profile of the basic romosozumab formulation of example 1, the combined effect of HPGCD and methionine was investigated.
- Romosozumab in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006
% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to 125 mg/mL or to 190 mg/mL using 30kDa Sartorius Viva Spin centrifugal spin filters. The spin tubes were centrifuged at 3000 rpm, 5° C. for 60 minutes; samples were mixed between spin cycles using a positive displacement pipette. - The required amount of methionine to produce 2.2 mL of sample with the required concentration (55 and 200 mM) was weighed (0.018 g and 0.066 g, respectively) using an analytical balance. The Methionine was dissolved in 2.2 mL of the appropriate protein solution (125 mg/mL or 190 mg/mL). The required amount of HPGCD to produce 1 mL of 30 mM HPGCD at the required concentration was weighed (0.053 g) using an analytical balance. 1 ml of the appropriate protein/methionine solution was used to dissolve the HPGCD.
- The formulations were buffer exchanged and concentrated as previously described in examples 1 and 2. The concentration of each sample was measured in duplicate before and after dialysis (Table 7) as previously described in examples 1 and 2. Results are reported as mean of duplicate sample readings.
-
TABLE 7 Replicates Sample 1 2 Mean SD % CV Pre-dialysis 120 mg/mL 55 mM 118.83 121.55 120.19 1.92 1.60 Meth + 30 mM HPGCD 120 mg/mL 200 mM 118.63 119.00 118.82 0.26 0.22 Meth + 30 mM HPGCD 180 mg/mL 55 mM 184.44 185.70 185.08 0.89 0.48 Meth + 30 mM HPGCD 180 mg/mL 200 mM 182.84 181.63 182.24 0.86 0.47 Meth + 30 mM HPGCD 90 mg/mL Control 90.93 91.32 91.13 0.27 0.30 120 mg/mL Control 118.18 119.16 118.67 0.69 0.58 180 mg/mL Control 182.90 183.31 183.11 0.29 0.16 Post-dialysis 120 mg/mL 55 mM 21.65 21.61 21.63 0.02 0.11 Meth + 30 mM HPGCD 120 mg/mL 200 mM 21.23 21.34 21.29 0.07 0.36 Meth + 30 mM HPGCD 180 mg/mL 55 mM 27.37 27.66 27.52 0.20 0.74 Meth + 30 mM HPGCD 180 mg/mL 200 mM 26.63 26.48 26.56 0.11 0.41 Meth + 30 mM HPGCD 90 mg/mL DS 22.51 22.60 22.56 0.06 0.28 120 mg/mL DS 23.54 23.57 23.56 0.02 0.10 120 mg/mL DS 31.47 31.30 31.39 0.12 0.39 - The pH of the formulations pre-dialysis and after 24 h confirmed the pH shift (Table 8).
-
TABLE 8 pH Viscosity Osmolality Sample t0 t24 (cP) (mOsmol) 120 mg/mL 55 mM 5.19 7.80 6.56 486 Meth + 30 mM HPGCD 120 mg/mL 200 mM 5.24 7.75 7.09 672 Meth + 30 mM HPGCD 180 mg/mL 55 mM 5.19 7.76 41.62 621 Meth + 30 mM HPGCD 180 mg/mL 200 mM 5.28 7.66 37.07 862 Meth + 30 mM HPGCD 90 mg/mL Control 5.27 7.86 2.55 321 120 mg/mL Control 5.22 7.80 4.76 320 180 mg/mL Control 5.28 7.77 27.21 398 Tissue buffer* 6.99 - Visual assessment of the sample was performed each hour for the first four hours. Results are reported in Table 9.
-
TABLE 9 120 mg/mL 120 mg/mL 180 mg/mL 180 mg/mL 55 mM 200 mM 55 mM 200 mM Meth + Meth + Meth + Meth + Time 30 mM 30 mM 30 mM 30 mM 90 mg/mL 120 mg/mL 180 mg/mL (hr) HPGCD HPGCD HPGCD HPGCD Control Control Control 0 No No No No No No No 1 Light Very Light Heavy Moderate Very Light Light Moderate 2 Heavy Moderate Heavy Heavy Moderate Moderate Very Heavy 3 Heavy Heavy Heavy Heavy Heavy Heavy Very Heavy 4 Heavy Heavy Heavy Heavy Heavy Heavy Very Heavy - The addition of HPGCD and methionine improved the rate of precipitation over the basic formulation, especially at high concentrations of romosozumab (180 mg/mL).
- Twenty different formulations comprising combinations of HPGCD and methionine with and without calcium acetate were made in order to investigate the additional concentrations of methionine and HPGCD and their effect on the pH, viscosity and osmolality.
- Romosozumab at 120 mg/mL in 50 mM sodium acetate, 14 mM calcium acetate, 6% sucrose, 0.006
% polysorbate 20 at pH 5.2 (drug solution, DS) was concentrated to −190 mg/mL using 30 kDaSartorius Viva Flow 50, bench scale tangential flow filtration (TFF) cartridge. System was run using a Masterflex peristaltic pump at a pressure of ˜2.5 Bar, ≥6x volume exchange. - Romosozumab at 120 mg/mL in DS was buffer exchanged to 55 mM sodium acetate, 6% sucrose, 0.006
% polysorbate 20, pH5.2 (without calcium acetate) and concentrated to ˜190 mg/mL using 30 kDaSartorius Viva Flow 50, bench scale tangential flow filtration (TFF) cartridge. System was run using a Masterflex peristaltic pump at a pressure of ˜2.5 Bar, ≥6x volume exchange. - Methionine and HPGCD were spiked according to the experiment design (Table 10).
-
TABLE 10 HPGCD mM Weight (g) Methionine mM Weight (g) 30 0.0529 55 0.0098 77.5 0.1366 127.5 0.0228 125 0.2203 200 0.0358 MW 1762 g/mol MW 149.21 g/ mol Volume 1 ml Volume 1.2 ml - The required amount of Methionine to produce 1.2 mL of sample with the required concentration was weighed using an analytical balance. The Methionine was dissolved in 2.2 mL of the appropriate protein solution (with/without calcium acetate). The required amount of HPGCD to produce 1 mL of sample at the required concentration was weighed using an analytical balance. 1 ml of the appropriate protein/methionine solution (with/without calcium acetate) was used to dissolve the HPGCD.
- Samples were run through the pH shift model. The pH and the concentrations were measure pre- and post-dialysis as described above. Pre-dialysis osmolality and viscosity were also measured in order to identify specific formulations which would meet the physiological requirements for subcutaneous administration. Table 11 shows the 20 newly designed formulations and the 6 controls run in this experiment.
-
TABLE 11 Concentration Formulation HPGCD Met Ca (mg/mL) Viscosity Osmolality pH # (mM) (mM) (14 mM) Mean (cP) (mOsmol) t0 t24 1 77.5 55 No 154.1 — 773.0 5.17 8.08 2 30 200 Yes 175.8 36.3 804.0 5.03 7.99 3 77.5 127.5 Yes 171.7 51.9 930.0 5.02 8.01 4 30 127.5 No 157.6 34.1 674.0 5.04 7.97 5 77.5 127.5 Yes 169.8 51.1 896.7 4.99 7.96 6 77.5 200 No 148.7 36.0 988.3 5.15 8.02 7 77.5 55 No 151.1 41.2 752.3 5.31 8.01 8 77.5 200 No 148.9 36.3 986.0 5.3 8.01 9 125 200 Yes 160.0 66.4 1305.5 5.25 8.08 10 30 55 Yes 178.4 36.5 590.3 5.32 8.05 11 77.5 127.5 Yes 174.0 51.8 908.3 5.2 8.00 12 30 127.5 No 160.4 27.5 654.0 5.13 8.04 13 125 55 Yes 167.7 73.2 1043.0 5.17 8.03 14 125 127.5 No 146.7 50.6 1149.0 5.22 8.05 15 125 127.5 No 146.8 52.4 1165.3 5.23 8.28 16 125 127.5 Yes 167.0 69.4 1198.0 5.18 8.04 17 77.5 55 Yes 177.5 53.3 819.0 5.15 8.15 18 77.5 200 Yes 173.5 48.6 1043.3 5.2 8.15 19 30 127.5 Yes 183.2 39.6 681.3 5.14 8.08 20 77.5 127.5 No 153.0 41.8 897.0 5.27 8.11 21 0 0 Yes 90.4 2.8 328.7 5.06 8.22 22 0 0 Yes 118.8 5.4 323.7 5.18 8.19 23 0 0 Yes 184.3 32.2 388.7 5.14 8.16 24 0 0 No 93.4 2.83 322.0 5.18 8.26 25 0 0 No 123.7 336.7 5.21 8.18 26 0 0 Yes 187.4 39.5 395.0 5.37 8.13 - The concentrations of the formulations pre-dialysis were measured and are shown in Table 11, fifth column; the post-dialysis concentrations were also measured and their trends were similar to those of formulations previously tested (data not shown). Pre- and post-dialysis pH, viscosity and osmolality were measured and are also illustrated in Table 11.
- Visual assessment of the sample was performed each hour for the first five hours. Results are reported in Table 12.
-
TABLE 12 hr 1 2 3 4 5 6 7 8 9 10 11 12 13 0 No No No No No No No No No No No No No 1 Very Light Very Very Very Mode Very Mode Light Heavy Light Very Mode Heavy Light Heavy Light rate Heavy rate Heavy rate 2 Very Mode Mode Very Mode Heavy Very Heavy Mode Very Mode Very Heavy Heavy rate rate Heavy rate Heavy rate Heavy rate Heavy 3 Very Heavy Heavy Very Mode Heavy Very Heavy Mode Very Heavy Very Heavy Heavy Heavy rate Heavy rate Heavy Heavy 4 Very Heavy Heavy Very Heavy Heavy Very Very Mode Very Very Very Very Heavy Heavy Heavy Heavy rate Heavy Heavy Heavy Heavy 5 Very Very Very Very Very Very Very Very Heavy Very Very Very Very Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy hr 14 15 16 17 18 19 20 21 22 23 24 25 26 0 No No No No No No No No No No No No No 1 Very Very Light Mode Mode Heavy Heavy No Light Very Mode Heavy Very Heavy Heavy rate rate Heavy rate Heavy 2 Very Very Mode Heavy Mode Very Very Light Mode Very Heavy Very Very Heavy Heavy rate rate Heavy Heavy rate Heavy Heavy Heavy 3 Very Very Mode Heavy Heavy Very Very Mode Heavy Very Heavy Very Very Heavy Heavy rate Heavy Heavy rate Heavy Heavy Heavy 4 Very Very Heavy Very Heavy Very Very Heavy Heavy Very Heavy Very Very Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy 5 Very Very Heavy Very Very Very Very Heavy Very Very Heavy Very Very Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy Heavy - All results were entered into statistical analysis package (
Software SAS JMP 11, version 11.0.0; 64 bit). Four formulations (details in Table 13, second column) were selected for further testing for having predicted osmolalities (˜800 mOsml up to ˜1000 mOsmol) and viscosities (<80 cP) suitable for desired pharmaceutical formulations. - To prepare the formulation comprising HPGCD and Methionine, it was required to buffer exchange and concentrate romosozumab from ˜119 mg/mL to ˜150 mg/mL and to ˜180 mg/ml; 6 x volume buffer exchanges was performed before concentration. Concentrations were measured using the Solo VPE high concentration UV spectrophotometer. Romosozumab Extinction Coefficient used was 1.50 ml/(mg*cm). Concentration was determined from duplicate readings. Buffer exchange and concentrations were performed in a
VivaSpin Spin 20, 30KD centrifugal spin filters using the centrifuge in 1 hour blocks at 3200 rpm, 5° C. The material was mixed using a positive displacement pipette between each spin. Samples were prepared in duplicate. After 20 spins all 6 volumes of buffer were added to perform the buffer exchange. Concentration of ˜150 mg/mL and ˜180 mg/mL were achieved for formulations B, C and D. - Due to issue to concentrate formulation A, it was decided to use capillary to concentrate this formulation and attain a concentration of 150 mg/mL and then one of 180 mg/ml. All material was sterile filtered using a 0.22 mm syringe filter and stored at 5° C. after preparation. Each sample was spiked with the corresponding 1
% polysorbate 20 to a concentration of 0.006%. All formulations were within ±5% of target concentration (Table 13). -
TABLE 13 Predicted Predicted Formulation Required Final Osmolality Viscosity # Details concentration Concentration (mOsmol) (cP) A 55 mM NaACE*, 14 mM 150 148.30 772.8 52.6 CaACE#, 6% sucrose, 0.006 % polysorbate 96 mM HPGCD, pH 5.2 180 176.87 800.4 64.6 B 55 mM NaACE*, 14 mM 150 152.25 773.5 42.8 CaACE#, 6% sucrose, 0.006 % polysorbate 20,180 182.12 801.1 54.8 78 mM HPGCD, 55 mM Methionine pH 5.2 C 55 mM NaACE*, 14 mM 150 151.02 771.5 33.1 CaACE#, 6% sucrose, 0.006 % polysorbate 20,180 186.24 799.1 45.1 55 mM HPGCD, 125 mM Methionine pH 5.2 D 55 mM NaACE*, 14 mM 150 151.21 955.3 40.5 CaACE#, 6% sucrose, 0.006 % polysorbate 20,80 mM HPγCD, 160 mM Methionine pH 5.2 180 183.48 982.9 52.3 *NaACE = Sodium Acetate; #CaACE = Calcium Acetate - The concentrations of these formulations were measured post-dialysis and concentrations were as expected following the same trends as for formulations previously tested (data not shown). The pre- and post-dialysis pHs of each of the formulations were measured along with the viscosities and osmolalities pre-dialysis and these results are reported in Table 14. In Table 14, A150 means formulation A as of Table 12 with 150 mg/mL of romosozumab, A180 means formulation A as of Table 13 with 180 mg/mL of romosozumab etc. Control formulations comprise the basic formulation of 55 mM sodium acetate, 14mM calcium acetate, 6% sucrose, 0.006
% polysorbate -
TABLE 14 pH Viscosity Osmolality Formulation t0 t24 (cP) (mOsmol) A 150 5.55 7.94 164.41 1680 A 180 # 8.12 # # B 150 5.61 8.05 133.16 748 B 180 5.57 8.02 594.17 # C 150 5.48 7.96 83.00 747 C 180 5.65 7.99 343.54 847 D 150 5.64 7.99 162.55 853 D 180 5.71 8.03 765.78 # Control 90 5.28 8.03 3.19 323 Control 120 5.22 7.99 6.09 326 Control 150 5.26 7.97 13.08 354 Control 180 5.26 7.99 27.2 386 Tissue Buffer 7.17 7.15 # = not enough sample to test - In summary, the combination of HPGCD and methionine has been found to be surprisingly beneficial for stabilizing antibodies, especially at high concentrations, in liquid formulations.
Claims (21)
1. A liquid pharmaceutical formulation comprising:
a. an antibody or an antigen-binding fragment thereof as an active ingredient;
b. cyclodextrin and
c. methionine.
2. The liquid formulation according to claim 1 comprising methionine at a concentration of from 7.5 mM to 200 mM.
3. The liquid formulation according to claim 1 comprising cyclodextrin at a concentration of from 7.5 mM to 250 mM.
4. The liquid formulation according to claim 1 comprising the antibody or the antigen-binding fragment thereof at a concentration of from 1 to 200 mg/ml, preferably from 90 to 180 mg/ml.
5. The liquid formulation according to claim 1 , wherein the antibody or the antigen-binding fragment thereof specifically binds human sclerostin.
6. The liquid formulation according to claim 1 wherein the antibody is a human or humanised antibody or antigen-binding fragment thereof.
7. The liquid formulation according to claim 1 , wherein:
a. the antibody or the antigen-binding fragment thereof
i. comprises CDR-H1 having the sequence as defined in SEQ ID NO:1; CDR-H2 having the sequence as defined in SEQ ID NO:2; CDR-H3 having the sequence as defined in SEQ ID NO:3; CDR-L1 having the sequence as defined in SEQ ID NO:4; CDR-L2 having the sequence as defined in SEQ ID NO:5 and CDR-L3 having the sequence as defined in SEQ ID NO:6; or
ii. has a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy variable region having the sequence as defined in SEQ ID NO: 8; or
b. the antibody has
i. a light chain having the sequence as defined in SEQ ID NO: 9 and a heavy chain having the sequence as defined in SEQ ID NO: 10; or
ii. a light chain having the sequence as defined in SEQ ID NO: 11 and a heavy chain having the sequence as defined in SEQ ID NO: 12.
8. The liquid formulation according to claim 1 , wherein the antibody is romosozumab.
9. The liquid formulation according to claim 1 having a pH of from 4.0 to 7.5.
10. The liquid formulation according to claim 1 wherein the cyclodextrin is selected from alpha-cyclodextrin, beta-cyclodextrin, dimethyl-beta-cyclodextrin, trimethyl-beta-cyclodextrin, randomly methylated beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (i.e. 2 hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin or 2,3-dihydroxypropyl-beta-cyclodextrin), hydroxyisobutyl-beta-cyclodextrin sulfobutylether beta-cyclodextrin, glucosyl-beta-cyclodextrin, maltosyl-beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-gamma-cyclodextrin (i.e. 2 hydroxypropyl-gamma-cyclodextrin, 3-hydroxypropyl-gamma-cyclodextrin or 2,3-dihydroxypropyl-gamma-cyclodextrin), cyclodextrin-containing polymers or combinations thereof.
11. The liquid formulation according to claim 10 , wherein the cyclodextrin is selected from hydroxypropyl-gamma-cyclodextrin.
12. The liquid formulation according to claim 1 wherein the formulation comprises from 1 mg/ml to 200 mg/ml of antibody, from 10 mM to 55 mM sodium acetate, from 0 to 14 mM calcium acetate, from 0 to 6% sucrose, from 0 to 0.006% polysorbate 20, from 55 mM to 80 mM hydroxypropyl-gamma-cyclodextrin, from 55 mM to 160 mM methionine at pH 5.2.
13. The liquid formulation according to claim 12 , wherein the formulation comprises from 90 mg/ml to 180 mg/ml, preferably from 120 mg/ml to 180 mg/ml of romosozumab.
14. The liquid formulation according to claim 1 wherein the liquid formulation is not a hydrogel.
15. The liquid formulation according to claim 1 wherein the liquid formulation comprises at least 2%, at least 5%, at least 10%, at least 25%, between 2% and 90%, between 2% and 75%, or between 2% and 50% water.
16. The liquid formulation according to claim 1 for use in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
17. A method for treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength in a mammalian subject comprising administering a therapeutically effective amount of the formulation of claim 1 .
18. Use of the liquid formulation according to any one of claims 1 in the manufacture of a medicament for the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength.
19. (canceled)
20. A method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation, the method comprising providing a liquid formulation and adding to the formulation methionine and cyclodextrin, preferably hydroxypropyl-gamma-cyclodextrin.
21. A method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of the formulation of claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/152,872 US20230355758A1 (en) | 2016-03-10 | 2023-01-11 | Pharmaceutical Formulations |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1604124.6A GB201604124D0 (en) | 2016-03-10 | 2016-03-10 | Pharmaceutical formulation |
GB1604124.6 | 2016-03-10 | ||
PCT/EP2017/055594 WO2017153541A1 (en) | 2016-03-10 | 2017-03-09 | Pharmaceutical formulation |
US201816083321A | 2018-09-07 | 2018-09-07 | |
US18/152,872 US20230355758A1 (en) | 2016-03-10 | 2023-01-11 | Pharmaceutical Formulations |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/083,321 Continuation US11576970B2 (en) | 2016-03-10 | 2017-03-09 | Pharmaceutical formulations |
PCT/EP2017/055594 Continuation WO2017153541A1 (en) | 2016-03-10 | 2017-03-09 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230355758A1 true US20230355758A1 (en) | 2023-11-09 |
Family
ID=55952141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/083,321 Active US11576970B2 (en) | 2016-03-10 | 2017-03-09 | Pharmaceutical formulations |
US18/152,872 Pending US20230355758A1 (en) | 2016-03-10 | 2023-01-11 | Pharmaceutical Formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/083,321 Active US11576970B2 (en) | 2016-03-10 | 2017-03-09 | Pharmaceutical formulations |
Country Status (18)
Country | Link |
---|---|
US (2) | US11576970B2 (en) |
EP (2) | EP4226915A1 (en) |
JP (2) | JP2019512540A (en) |
CN (2) | CN114767849A (en) |
CA (1) | CA3016117A1 (en) |
DK (1) | DK3426294T3 (en) |
ES (1) | ES2946259T3 (en) |
FI (1) | FI3426294T3 (en) |
GB (1) | GB201604124D0 (en) |
HR (1) | HRP20230733T1 (en) |
HU (1) | HUE062429T2 (en) |
LT (1) | LT3426294T (en) |
MA (1) | MA43705A (en) |
PL (1) | PL3426294T3 (en) |
PT (1) | PT3426294T (en) |
RS (1) | RS64337B1 (en) |
SI (1) | SI3426294T1 (en) |
WO (1) | WO2017153541A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
UA127219C2 (en) * | 2017-07-27 | 2023-06-14 | Джянгсу Хенгруй Медісін Ко., Лтд. | Sost antibody pharmaceutical composition and uses thereof |
US11466079B2 (en) * | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
US20210308265A1 (en) * | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
PE20212185A1 (en) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | FORMULATION OF THERAPEUTIC ANTIBODIES |
WO2023098694A1 (en) * | 2021-11-30 | 2023-06-08 | 江苏恒瑞医药股份有限公司 | Anti-sost antibody pharmaceutical composition and use thereof |
WO2023224112A1 (en) * | 2022-05-20 | 2023-11-23 | 株式会社ダイセル | Liquid pharmaceutical composition |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (en) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Device for the quantitative and qualitative detection of hydrocarbon-containing suspended particles in gases |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (en) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | Hiv-resistant recombined modified antibody and method for preparing modified antibody |
US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
JPH06502311A (en) | 1990-10-22 | 1994-03-17 | フォックス・チェイス・キャンサー・センター | DNA structure to provide RNA therapy |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
RU2139351C1 (en) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence |
US5864027A (en) | 1993-06-07 | 1999-01-26 | Genentech, Inc. | HIV envelope polypeptides |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
DE4427221A1 (en) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induced osteoclast modulation for osteoporosis therapy |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
ATE403001T1 (en) | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | ANTIGEN BINDING FRAGMENTS SPECIFICALLY DETECTING CANCER CELLS, NUCLEOTIDES ENCODING THESE FRAGMENTS, AND THEIR USE IN PREVENTING AND DETECTING CANCER |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
DK0985039T3 (en) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Artificial antibody polypeptides |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
EP1367124A1 (en) | 1997-08-01 | 2003-12-03 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
PT2261335T (en) | 1998-11-27 | 2017-09-08 | Ucb Pharma Sa | Compositions and methods for increasing bone mineralisation |
JP2002536968A (en) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Antibodies specific for KDR and uses thereof |
ES2332916T3 (en) | 1999-06-09 | 2010-02-15 | Genentech Inc | COMPOSITIONS AND METHOD FOR TUMOR TREATMENT. |
EP1266000A1 (en) | 2000-03-02 | 2002-12-18 | Amgen Inc. | Chordin-like-2 molecules and uses thereof |
JP2003534813A (en) | 2000-06-01 | 2003-11-25 | アムジェン インコーポレーテッド | Cystine knot polypeptide: CLOAKED-2 molecule and its use |
US20040132021A1 (en) | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (en) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA · 1 · -pyrrolines |
EP1451560B1 (en) | 2001-12-06 | 2017-11-29 | BioControl Systems, Inc. | Sample collection and testing system |
US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
EP2277522B1 (en) | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
AU2003304107B2 (en) | 2002-11-01 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
JP4660471B2 (en) | 2003-03-14 | 2011-03-30 | セルテック アール アンド ディー, インコーポレイテッド | TGFβ binding protein ligands and uses thereof |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (en) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT |
MEP2808A (en) | 2003-06-16 | 2010-02-10 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
EP1691825B1 (en) | 2003-12-11 | 2011-09-28 | Ares Trading S.A. | Stabilized interferon liquid formulations |
US7879320B2 (en) | 2004-05-17 | 2011-02-01 | Ares Trading S.A. | Hydrogel interferon formulations |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
WO2006015373A2 (en) | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
PE20061201A1 (en) * | 2005-01-28 | 2006-11-03 | Wyeth Corp | STABILIZED LIQUID FORMULATIONS OF POLYPEPTIDE |
GT200600031A (en) * | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
AR053553A1 (en) * | 2005-03-08 | 2007-05-09 | Pharmacia & Upjohn Co Llc | COMPOSITION OF ANTI BODIES ANTI MOLECULA OF CELLULAR ADRESIN MUCOSA (ANTI-MADCAM) |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
LT3345607T (en) | 2006-12-29 | 2023-01-10 | Ossifi-Mab Llc | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
US20100028335A1 (en) | 2007-02-02 | 2010-02-04 | Novartis Ag | Compositions and Methods to Treat Bone Related Disorders |
US7744874B2 (en) | 2007-03-20 | 2010-06-29 | Eli Lilly And Company | Anti-sclerostin antibodies |
JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
TWI489993B (en) | 2007-10-12 | 2015-07-01 | Novartis Ag | Compositions and methods of use for antibodies against sclerostin |
EA201000718A1 (en) | 2007-11-02 | 2011-06-30 | Новартис Аг | MOLECULES AND METHODS DESIGNED TO MODULATE THE RELATED LIPOPROTEIDES RECEPTOR OF LOW DENSITY PROTEIN 6 (LRP6) |
MX2010006519A (en) | 2007-12-14 | 2010-10-15 | Amgen Inc | Method for treating bone fracture with anti-sclerostin antibodies. |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102281903B (en) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
DE102009056745A1 (en) | 2009-12-04 | 2011-06-09 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the administration of peptides |
EP3195880B1 (en) * | 2010-05-14 | 2019-11-27 | Amgen Inc. | High concentration anti-sclerostin antibody formulations |
EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
ES2863626T3 (en) | 2010-10-27 | 2021-10-11 | Amgen Inc | DKK1 antibodies and methods of use |
JP2015509526A (en) * | 2012-03-07 | 2015-03-30 | カディラ ヘルスケア リミティド | Pharmaceutical formulation |
-
2016
- 2016-03-10 GB GBGB1604124.6A patent/GB201604124D0/en not_active Ceased
-
2017
- 2017-03-09 CN CN202210422445.3A patent/CN114767849A/en active Pending
- 2017-03-09 SI SI201731355T patent/SI3426294T1/en unknown
- 2017-03-09 EP EP23163723.2A patent/EP4226915A1/en active Pending
- 2017-03-09 ES ES17710208T patent/ES2946259T3/en active Active
- 2017-03-09 HU HUE17710208A patent/HUE062429T2/en unknown
- 2017-03-09 MA MA043705A patent/MA43705A/en unknown
- 2017-03-09 CA CA3016117A patent/CA3016117A1/en active Pending
- 2017-03-09 HR HRP20230733TT patent/HRP20230733T1/en unknown
- 2017-03-09 WO PCT/EP2017/055594 patent/WO2017153541A1/en active Application Filing
- 2017-03-09 DK DK17710208.4T patent/DK3426294T3/en active
- 2017-03-09 US US16/083,321 patent/US11576970B2/en active Active
- 2017-03-09 PL PL17710208.4T patent/PL3426294T3/en unknown
- 2017-03-09 CN CN201780016205.0A patent/CN108883175A/en active Pending
- 2017-03-09 LT LTEPPCT/EP2017/055594T patent/LT3426294T/en unknown
- 2017-03-09 FI FIEP17710208.4T patent/FI3426294T3/en active
- 2017-03-09 PT PT177102084T patent/PT3426294T/en unknown
- 2017-03-09 EP EP17710208.4A patent/EP3426294B1/en active Active
- 2017-03-09 JP JP2018566642A patent/JP2019512540A/en active Pending
- 2017-03-09 RS RS20230537A patent/RS64337B1/en unknown
-
2022
- 2022-01-07 JP JP2022001395A patent/JP2022062014A/en active Pending
-
2023
- 2023-01-11 US US18/152,872 patent/US20230355758A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114767849A (en) | 2022-07-22 |
JP2019512540A (en) | 2019-05-16 |
CA3016117A1 (en) | 2017-09-14 |
LT3426294T (en) | 2023-06-26 |
US20190083617A1 (en) | 2019-03-21 |
RS64337B1 (en) | 2023-08-31 |
EP3426294A1 (en) | 2019-01-16 |
WO2017153541A1 (en) | 2017-09-14 |
PL3426294T3 (en) | 2023-10-16 |
EP3426294B1 (en) | 2023-05-17 |
HRP20230733T1 (en) | 2023-10-13 |
DK3426294T3 (en) | 2023-06-26 |
CN108883175A (en) | 2018-11-23 |
GB201604124D0 (en) | 2016-04-27 |
FI3426294T3 (en) | 2023-06-20 |
US11576970B2 (en) | 2023-02-14 |
PT3426294T (en) | 2023-06-06 |
MA43705A (en) | 2018-11-28 |
JP2022062014A (en) | 2022-04-19 |
EP4226915A1 (en) | 2023-08-16 |
SI3426294T1 (en) | 2023-09-29 |
HUE062429T2 (en) | 2023-11-28 |
ES2946259T3 (en) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230355758A1 (en) | Pharmaceutical Formulations | |
EP2569010B1 (en) | High concentration antibody formulations | |
EP3454899B1 (en) | Pharmaceutical composition | |
JP2013525484A (en) | Compositions and methods useful for reducing the viscosity of protein-containing formulations | |
TW201414491A (en) | Anti-prolactin receptor antibody formulations | |
EP3256154B1 (en) | Pharmaceutical formulation comprising antibody | |
US11857625B2 (en) | Pharmaceutical compositions | |
JP2021519754A (en) | C-terminal antibody variant | |
EA041921B1 (en) | PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UCB BIOPHARMA SRL, BELGIUM Free format text: CHANGE OF NAME;ASSIGNOR:UCB BIOPHARMA SPRL;REEL/FRAME:062388/0117 Effective date: 20191202 |
|
AS | Assignment |
Owner name: UCB BIOPHARMA SRL, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YATES, ANDREW JEFFREY;CLIPSTONE, JAMES GREGORY;REEL/FRAME:062731/0569 Effective date: 20230203 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |